<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60831</article-id><article-id pub-id-type="doi">10.7554/eLife.60831</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-198254"><name><surname>Li</surname><given-names>Guorong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198255"><name><surname>Lee</surname><given-names>Chanyoung</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198256"><name><surname>Read</surname><given-names>A Thomas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198257"><name><surname>Wang</surname><given-names>Ke</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-224719"><name><surname>Ha</surname><given-names>Jungmin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-224720"><name><surname>Kuhn</surname><given-names>Megan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198258"><name><surname>Navarro</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198259"><name><surname>Cui</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198260"><name><surname>Young</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198261"><name><surname>Gorijavolu</surname><given-names>Rahul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198262"><name><surname>Sulchek</surname><given-names>Todd</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198263"><name><surname>Kopczynski</surname><given-names>Casey</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2173-8309</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-117673"><name><surname>Farsiu</surname><given-names>Sina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198264"><name><surname>Samples</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-198265"><name><surname>Challa</surname><given-names>Pratap</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-198266"><name><surname>Ethier</surname><given-names>C Ross</given-names></name><email>ross.ethier@bme.gatech.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-170111"><name><surname>Stamer</surname><given-names>W Daniel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2504-8997</contrib-id><email>dan.stamer@duke.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf6"/></contrib><aff id="aff1"><label>1</label><institution>Department of Ophthalmology, Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Biomedical Engineering, Georgia Institute of Technology/Emory University</institution><addr-line><named-content content-type="city">Atlanta</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Mechanical Engineering, Georgia Institute of Technology</institution><addr-line><named-content content-type="city">Atlanta</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Aerie Pharmaceuticals, Inc</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Biomedical Engineering, Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Washington State University Floyd Elson School of Medicine</institution><addr-line><named-content content-type="city">Spokane</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib><contrib contrib-type="editor"><name><surname>Smith</surname><given-names>Lois</given-names></name><role>Reviewing Editor</role><aff><institution>Boston Children's Hospital/Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>30</day><month>03</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e60831</elocation-id><history><date date-type="received" iso-8601-date="2020-07-08"><day>08</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-03-12"><day>12</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Li et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Li et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-60831-v1.pdf"/><abstract><p>Glucocorticoids are widely used as an ophthalmic medication. A common, sight-threatening adverse event of glucocorticoid usage is ocular hypertension, caused by dysfunction of the conventional outflow pathway. We report that netarsudil, a rho-kinase inhibitor, decreased glucocorticoid-induced ocular hypertension in patients whose intraocular pressures were poorly controlled by standard medications. Mechanistic studies in our established mouse model of glucocorticoid-induced ocular hypertension show that netarsudil both prevented and reduced intraocular pressure elevation. Further, netarsudil attenuated characteristic steroid-induced pathologies as assessed by quantification of outflow function and tissue stiffness, and morphological and immunohistochemical indicators of tissue fibrosis. Thus, rho-kinase inhibitors act directly on conventional outflow cells to prevent or attenuate fibrotic disease processes in glucocorticoid-induced ocular hypertension in an immune-privileged environment. Moreover, these data motivate the need for a randomized prospective clinical study to determine whether netarsudil is indeed superior to first-line anti-glaucoma drugs in lowering steroid-induced ocular hypertension.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>steroid glaucoma</kwd><kwd>glaucoma medications</kwd><kwd>trabecular meshwork</kwd><kwd>fibrosis</kwd><kwd>contractility</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>EY030124</award-id><principal-award-recipient><name><surname>Farsiu</surname><given-names>Sina</given-names></name><name><surname>Stamer</surname><given-names>W Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>EY031710</award-id><principal-award-recipient><name><surname>Ethier</surname><given-names>C Ross</given-names></name><name><surname>Stamer</surname><given-names>W Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>EY005722</award-id><principal-award-recipient><name><surname>Stamer</surname><given-names>W Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006312</institution-id><institution>BrightFocus Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Li</surname><given-names>Guorong</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001818</institution-id><institution>Research to Prevent Blindness</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Stamer</surname><given-names>W Daniel</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008065</institution-id><institution>Georgia Research Alliance</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ethier</surname><given-names>C Ross</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Aerie Pharmaceuticals</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Stamer</surname><given-names>W Daniel</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>An FDA-approved, rho-associated kinase inhibitor reverses fibrosis in the conventional outflow pathway of a mouse model of glaucoma and reverses ocular hypertension in patients with steroid glaucoma.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Topical glucocorticoids (GCs) are routinely used after ocular surgery and to treat common ocular disorders such as uveitis and macular edema (<xref ref-type="bibr" rid="bib50">Noble and Goa, 1998</xref>; <xref ref-type="bibr" rid="bib15">Haeck et al., 2011</xref>). Unfortunately, ocular hypertension (OHT, i.e. elevated intraocular pressure [IOP]) is a common adverse event of such treatment, which can progress to a form of secondary glaucoma known as steroid-induced glaucoma. Interestingly, 90% of people with primary open-angle glaucoma (POAG), the most common type of glaucoma, develop OHT after GC treatment (<xref ref-type="bibr" rid="bib4">Becker, 1965</xref>). This is more than double the rate of the general population, likely because GCs increase extracellular matrix (ECM) material, cell contractility, and stiffness in an already dysfunctional conventional outflow pathway (<xref ref-type="bibr" rid="bib24">Johnson et al., 1997</xref>; <xref ref-type="bibr" rid="bib81">Zhou et al., 1998</xref>), as is found in POAG (<xref ref-type="bibr" rid="bib59">Rönkkö et al., 2007</xref>; <xref ref-type="bibr" rid="bib70">Tamm and Fuchshofer, 2007</xref>). The conventional outflow pathway drains the majority of the aqueous humor, and its hydrodynamic resistance is the primary determinant and homeostatic regulator of IOP (<xref ref-type="bibr" rid="bib68">Tamm, 2009</xref>). Thus, pro-fibrotic changes in this outflow pathway, such as occurring with GC treatment, frequently lead to significantly elevated IOPs (<xref ref-type="bibr" rid="bib39">Liu et al., 2018</xref>).</p><p>Rho-associated protein kinase (ROCK) is a major cytoskeletal regulator in health and disease. Indeed, ROCK mediates pro-fibrotic processes in many tissues and pathological conditions, including fibrotic kidney disease (<xref ref-type="bibr" rid="bib48">Musso et al., 2017</xref>), idiopathic pulmonary fibrosis (<xref ref-type="bibr" rid="bib42">Marinković et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Knipe et al., 2015</xref>), cardiac fibrosis (<xref ref-type="bibr" rid="bib51">Olson, 2008</xref>; <xref ref-type="bibr" rid="bib16">Haudek et al., 2009</xref>), liver fibrosis, intestinal fibrotic strictures associated with Crohn’s disease (<xref ref-type="bibr" rid="bib11">Crespi et al., 2020</xref>), vitreoretinal disease (<xref ref-type="bibr" rid="bib79">Yamaguchi et al., 2017</xref>), and lens capsule opacity (<xref ref-type="bibr" rid="bib31">Korol et al., 2016</xref>). Hence, rho-kinase inhibitors (ROCKi) have been evaluated as anti-fibrotic therapeutics in multiple contexts. However, the mechanisms underlying their anti-fibrotic activity are complex and multifactorial due to the central involvement of ROCK in many cellular processes. Thus, tissue/pathology-specific studies are essential to evaluate the efficacy of ROCKis as anti-fibrotic agents.</p><p>Mechanistic studies evaluating anti-fibrotic activity of ROCKi in the eye are particularly interesting in view of the eye’s immune-privileged status (<xref ref-type="bibr" rid="bib67">Streilein, 2003</xref>), which minimizes the role of macrophages and monocytes as compared to other organ systems. In fact, OHT in glaucoma patients is the only approved indication for ROCKi in humans thus far (<xref ref-type="bibr" rid="bib60">Roskoski, 2020</xref>). Specifically, two ROCKi, ripasudil and netarsudil (NT), have been approved for clinical use to treat OHT in glaucoma patients because of their safety profile and IOP-lowering ability and ultimately their unique mechanism of action (<xref ref-type="bibr" rid="bib13">Garnock-Jones, 2014</xref>; <xref ref-type="bibr" rid="bib22">Isobe et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Tanihara et al., 2015</xref>; <xref ref-type="bibr" rid="bib30">Kopczynski and Heah, 2018</xref>; <xref ref-type="bibr" rid="bib64">Serle et al., 2018</xref>). Therefore, ROCKi are the only available glaucoma drug class that directly targets and improves conventional outflow function (<xref ref-type="bibr" rid="bib61">Schehlein and Robin, 2019</xref>). However, their use is currently limited to patients whose IOPs are inadequately controlled by medications that target other ocular sites. We here show that local delivery of the ROCKi, NT, significantly lowers IOP in two cohorts of steroid-induced glaucoma patients refractory to conventional medications. Moreover, we help define NT’s mechanism of restorative, anti-fibrotic action in treating steroid-induced OHT using our established mouse model (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>NT lowered IOP in steroid-induced glaucoma patients whose OHT was poorly controlled by standard glaucoma medications</title><p>Based on changes to the trabecular meshwork (TM) previously observed in studies of steroid glaucoma (<xref ref-type="bibr" rid="bib24">Johnson et al., 1997</xref>; <xref ref-type="bibr" rid="bib52">Overby et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>), we tested NT’s efficacy at lowering IOP in steroid-induced ocular hypertensive patients who did not respond well to standard first-line treatments. We retrospectively reviewed patient records, forming two cohorts of subjects from three treatment locations. The first cohort was created by an unbiased retrospective search of the Duke Eye Center’s electronic medical records using the key words, ‘steroid responder/glaucoma’ and ‘netarsudil’. Our search identified 21 eyes of 19 patients (mean age 66.8 years), treated with GCs for a variety of ocular conditions and who demonstrated OHT secondary to GC treatment (<xref ref-type="table" rid="table1">Table 1</xref>, cohort 1). In accordance with current standard of treatment, these steroid-responsive patients were initially treated with aqueous humor suppressants (e.g., carbonic anhydrase inhibitors and/or adrenergics, <xref ref-type="table" rid="table1">Table 1</xref>). We note that prostaglandin analogues were typically used as second-line therapies (or not at all) in this patient cohort, due to concerns about the possible pro-inflammatory effects of these agents (<xref ref-type="table" rid="table1">Table 1</xref>). Unfortunately, these first- and second-line medications did not adequately control IOP in these patients, who presented with an average IOP of 24.3 ± 6.6 mmHg before NT treatment (mean ± SD). Thus, NT treatment was initiated, resulting in a clinically significant lowering of IOP in all patients within 1 month, presenting an average IOP decrease of 7.9 mmHg (p=1.2×10<sup>−7</sup>, <xref ref-type="fig" rid="fig1">Figure 1A</xref>). In this cohort, IOP was reduced to an average of 16.4 ± 4.9 mmHg, which is within the normal range. IOPs over a 3-month course of treatment for each patient are shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. It is important to note that none of the patients were ‘tapered’ from their steroid during the first month of treatment, and thus the observed IOP lowering cannot be due to a removal of steroid.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Netarsudil (NT) efficaciously lowered intraocular pressure (IOP) in patients with steroid-induced elevated IOP poorly controlled with standard glaucoma medications.</title><p>IOPs were measured by Goldmann applanation tonometry in patients who demonstrated ocular hypertension (OHT) after steroid treatment for a variety of ocular conditions (<xref ref-type="table" rid="table1">Table 1</xref>). These individuals were initially treated with aqueous humor suppressants and/or prostaglandin analogues but showed persistent OHT, and were thus treated with NT. (A) Shows IOPs of patient cohort 1 (n = 21 eyes of 19 patients) and (B) Shows IOPs of patient cohort 2 (n = 11 eyes of 8 patients). ‘Before NT’ indicates IOPs measured before initiating NT in these patients, and ‘after NT’ shows IOP after daily treatment with NT for 1 month or less. The central line in box and whisker represents the median, the top and bottom edges are 25th and 75th percentiles, respectively, the whiskers extend to the most extreme data points, and ‘+’ indicates the mean. Empty symbols were statistically determined to be outliers of data sets. ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Time course of netarsudil (NT) effects on intraocular pressure (IOP) in patients with steroid-induced elevated IOP poorly controlled with standard glaucoma medications.</title><p>IOPs were measured by Goldmann applanation tonometry in patients who demonstrated ocular hypertension (OHT) after steroid treatment for a variety of ocular conditions (<xref ref-type="table" rid="table1">Table 1</xref>). These individuals were initially treated with aqueous humor suppressants and/or prostaglandin analogues but showed persistent OHT, and were thus treated with NT. We show IOPs of the subset of individual patients in cohort 1 that were monitored over 3 months of treatment. ‘Before NT’ indicates IOPs measured before initiating NT in these patients, and ‘after NT’ shows IOP after daily treatment with NT. Source data for patient IOPs in <xref ref-type="table" rid="table1">Table 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig1-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Netarsudil (NT) effectively lowered steroid-induced ocular hypertension in patients whose IOP was not well controlled with standard glaucoma medications.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Patient/ eye</th><th valign="top">Age <break/>(years)</th><th valign="top">Gender</th><th valign="top">Race</th><th valign="top">Ocular condition</th><th valign="top">Steroid type</th><th valign="top">Glaucoma medications</th><th valign="top">IOP before NT (mmHg)</th><th valign="top">IOP &lt; 1 month after NT <break/>(mmHg)</th></tr></thead><tbody><tr><td colspan="9" valign="top">Cohort 1</td></tr><tr><td valign="top">1/OD</td><td valign="top">50</td><td valign="top">M</td><td valign="top">AA</td><td valign="top">POAG</td><td valign="top">Durezol</td><td valign="top">Brim, Cos</td><td valign="top">23</td><td valign="top">16</td></tr><tr><td valign="top">2/OD</td><td valign="top">74</td><td valign="top">F</td><td valign="top">AA</td><td valign="top">CACG</td><td valign="top">PF</td><td valign="top">Apra, Meth, Lat</td><td valign="top">33</td><td valign="top">22</td></tr><tr><td valign="top">3/OD</td><td valign="top">27</td><td valign="top">M</td><td valign="top">HIS</td><td valign="top">TG</td><td valign="top">PF</td><td valign="top">Bet, Brim, Dor; Lum</td><td valign="top">36</td><td valign="top">28</td></tr><tr><td valign="top">4/OD</td><td valign="top">66</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">Uveitis</td><td valign="top">Retisert</td><td valign="top">Cos, Brim</td><td valign="top">17</td><td valign="top">9</td></tr><tr><td valign="top">5/OS</td><td valign="top">76</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">POAG</td><td valign="top">PF</td><td valign="top">Lum, Cos</td><td valign="top">17</td><td valign="top">11</td></tr><tr><td valign="top">6/OS</td><td valign="top">53</td><td valign="top">M</td><td valign="top">CAU</td><td valign="top">SR</td><td valign="top">Ozurdex</td><td valign="top">Com, Dor</td><td valign="top">31</td><td valign="top">12</td></tr><tr><td valign="top">7/OS</td><td valign="top">74</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">SR</td><td valign="top">PF</td><td valign="top">Cos, Brim</td><td valign="top">25</td><td valign="top">16</td></tr><tr><td valign="top">8/OS</td><td valign="top">61</td><td valign="top">F</td><td valign="top">AA</td><td valign="top">Uveitis</td><td valign="top">Durezol</td><td valign="top">Cos, Brim, Lat</td><td valign="top">34</td><td valign="top">26</td></tr><tr><td valign="top">9/OD</td><td valign="top">81</td><td valign="top">M</td><td valign="top">UNK</td><td valign="top">POAG</td><td valign="top">PF</td><td valign="top">Cos, Brim, Lat</td><td valign="top">25</td><td valign="top">19</td></tr><tr><td valign="top">9/OS</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">20</td><td valign="top">16</td></tr><tr><td valign="top">10/OS</td><td valign="top">51</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">Uveitis; SR</td><td valign="top">PF; Fluti</td><td valign="top">Cos, Brim</td><td valign="top">26</td><td valign="top">15</td></tr><tr><td valign="top">11/OS</td><td valign="top">78</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">POAG; SR</td><td valign="top">Oral Pred</td><td valign="top">Lat, Tim, Dor, Dmx</td><td valign="top">22</td><td valign="top">12</td></tr><tr><td valign="top">12/OD</td><td valign="top">76</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">SIG</td><td valign="top">Lotemax</td><td valign="top">Brim, Cos, Vyzulta</td><td valign="top">28</td><td valign="top">20</td></tr><tr><td valign="top">12/OS</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">27</td><td valign="top">19</td></tr><tr><td valign="top">13/OD</td><td valign="top">62</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">SIG</td><td valign="top">PF</td><td valign="top">Tim, Dor, Lat</td><td valign="top">21</td><td valign="top">15</td></tr><tr><td valign="top">14/OD</td><td valign="top">78</td><td valign="top">M</td><td valign="top">AA</td><td valign="top">POAG; SR</td><td valign="top">PF</td><td valign="top">Com, Dor, Lat</td><td valign="top">30</td><td valign="top">13</td></tr><tr><td valign="top">15/OS</td><td valign="top">72</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">LTG; SIG</td><td valign="top">PF</td><td valign="top">Brim, Lat</td><td valign="top">15</td><td valign="top">13</td></tr><tr><td valign="top">16/OS</td><td valign="top">83</td><td valign="top">F</td><td valign="top">AA</td><td valign="top">Glaucoma</td><td valign="top">PF; Retisert</td><td valign="top">Com, Lat</td><td valign="top">21</td><td valign="top">18</td></tr><tr><td valign="top">17/OD</td><td valign="top">76</td><td valign="top">M</td><td valign="top">CAU</td><td valign="top">POAG; SIG</td><td valign="top">Durezol</td><td valign="top">Cos, Brim</td><td valign="top">12</td><td valign="top">10</td></tr><tr><td valign="top">18/OS</td><td valign="top">83</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">POAG; SIG</td><td valign="top">PF</td><td valign="top">Cos, Brim</td><td valign="top">29</td><td valign="top">18</td></tr><tr><td valign="top">19/OD</td><td valign="top">49</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">POAG; SIG</td><td valign="top">Lotemax</td><td valign="top">Cos, Brim</td><td valign="top">18</td><td valign="top">17</td></tr><tr><td valign="top"/><td valign="top">66.8</td><td valign="top">6M/13F</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">2.7 ± 0.7</td><td valign="bottom">24.3 ± 6.6</td><td valign="bottom">16.4 ± 4.9</td></tr><tr><td colspan="9" valign="top">Cohort 2</td></tr><tr><td valign="top">20/OS</td><td valign="top">60</td><td valign="top">M</td><td valign="top">CAU</td><td valign="top">Uveitis</td><td valign="top">Ivt. Dex</td><td valign="top">Com, Lat</td><td valign="top">60</td><td valign="top">44</td></tr><tr><td valign="top">21/OS</td><td valign="top">92</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">SR</td><td valign="top">Ozurdex</td><td valign="top">Lat, Alph, Dor, Tim</td><td valign="top">17</td><td valign="top">12</td></tr><tr><td valign="top">22/OD</td><td valign="top">77</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">SR</td><td valign="top">Oral Pred</td><td valign="top">Lat</td><td valign="top">24</td><td valign="top">19</td></tr><tr><td valign="top">22/OS</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">24</td><td valign="top">18</td></tr><tr><td valign="top">23/OD</td><td valign="top">65</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">SR</td><td valign="top">Ozurdex</td><td valign="top">Lum</td><td valign="top">30</td><td valign="top">26</td></tr><tr><td valign="top">23/OS</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">33</td><td valign="top">22</td></tr><tr><td valign="top">24/OD</td><td valign="top">16</td><td valign="top">F</td><td valign="top">CAU</td><td valign="top">PCG</td><td valign="top">Topical Pred</td><td valign="top">Tim, Azo, Lat</td><td valign="top">21</td><td valign="top">16</td></tr><tr><td valign="top">25/OD</td><td valign="top">67</td><td valign="top">M</td><td valign="top">CAU</td><td valign="top">POAG</td><td valign="top">Topical Pred</td><td valign="top">Lat, Azo, Bet</td><td valign="top">28</td><td valign="top">18</td></tr><tr><td valign="top">26/OS</td><td valign="top">3d</td><td valign="top">M</td><td valign="top">CAU</td><td valign="top">POAG</td><td valign="top">Oral Pred</td><td valign="top">Tim, Lat, Alph</td><td valign="top">44</td><td valign="top">32</td></tr><tr><td valign="top">27/OD</td><td valign="top">90</td><td valign="top">M</td><td valign="top">CAU</td><td valign="top">POAG</td><td valign="top">Topical Pred</td><td valign="top">Azo, Lat</td><td valign="top">22</td><td valign="top">16</td></tr><tr><td valign="top">27/OS</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">22</td><td valign="top">16</td></tr><tr><td valign="top"/><td valign="top">58.4</td><td valign="top">4M/4F</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">2.4 ± 1.1</td><td valign="top">26.5 ± 7.7</td><td valign="top">19.5 ± 5.8</td></tr></tbody></table><table-wrap-foot><fn><p>IOP, intraocular pressure; OD, right eye; OS, left eye; M, male; F, female; AA, African American; HIS, Hispanic; CAU, Caucasian; UNK, unknown; POAG, primary open-angle glaucoma; CACG, chronic angle-closure glaucoma; TG, traumatic glaucoma; OHT, ocular hypertension; PCG primary congenital glaucoma; PF=Pred Forte; Dex=Dexamethasone; Pred=Prednisone; Ivt=intravitreal; Brim=Brimonidine; Com=Combigan; Cos=Cosopt; Apra=Apraclonidine; Meth=Methazolamide; Lat=Latanoprost, Bet=Betaxolol; Dor=Dorzolamide; Lum=Lumigan; Com=Combigan; Alph=Alphagan; Tim=Timolol; Azo=Azopt. IOPs of patient 10/OS were statistically determined to be outliers and the numbers are removed from the analysis.</p></fn></table-wrap-foot></table-wrap><p>To evaluate NT efficacy in a second cohort of patients, a retrospective chart review was conducted on all patients seen by an experienced glaucoma specialist (JRS) over a 1-month period at two geographic locations. This cohort included patients with a single diagnosis of steroid-induced glaucoma that was uncontrolled on standard glaucoma medications, and who subsequently received NT. We identified 11 eyes from eight patients, with an average age of 58.4 years (<xref ref-type="table" rid="table1">Table 1</xref>, Cohort 2). The IOP in these eyes prior to NT treatment was similar to the first cohort at 26.5 ± 7.7 mmHg (mean ± SD). As well, NT significantly lowered IOP in this second cohort by an average of 7.0 mmHg (p=0.0003, <xref ref-type="fig" rid="fig1">Figure 1B</xref>), leading to an IOP of 19.5 ± 5.8 mmHg (mean ± SD). We conclude that NT significantly lowers IOP in steroid glaucoma patients who were refractory to conventional anti-ocular hypertensive medications.</p></sec><sec id="s2-2"><title>Increase in outflow facility by NT effectively prevents and reverses steroid-induced OHT in a mouse model of human disease</title><p>To better understand the mechanism of NT’s IOP-lowering effect in patients, we carried out studies utilizing our established steroid-induced OHT mouse model (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). It is known that daily treatment with NT significantly decreases IOP in naïve mouse eyes by improving conventional outflow function (<xref ref-type="bibr" rid="bib35">Li et al., 2016</xref>). Thus, we studied the efficacy of NT treatment in mice, focusing specifically on NT’s effect on conventional aqueous outflow dynamics and TM structure and function. Our experimental studies were designed to address two clinically important questions in this mouse model: (1) Can NT prevent steroid-induced OHT? and (2) can NT reverse steroid-induced OHT?</p><p>To test for prevention, mice were treated unilaterally with either NT or placebo (PL) starting 1 day prior to bilateral delivery of dexamethasone (DEX)-loaded nanoparticles (NPs), with NT or PL treatment continuing for the 4-week duration of DEX-NP exposure. Baseline IOPs in both NT and PL groups were similar (19.4 ± 0.4 and 19.6 ± 1.1 mmHg, respectively, p=0.60). One day after NT or PL treatment, but before DEX treatment, IOP was 20.1 ± 0.9 mmHg in PL-treated eyes and significantly lower (16.1 ± 1.4 mmHg) in NT-treated eyes (p=0.0009, <xref ref-type="fig" rid="fig2">Figure 2A</xref>). IOPs were followed for 4 weeks, and average IOP elevation in PL-treated eyes was 5.94 ± 0.57 mmHg, while IOP in NT-treated eyes was significantly lower than IOP in PL eyes (p&lt;0.0001, <xref ref-type="fig" rid="fig2">Figure 2B</xref>), returning close to baseline levels (average IOP elevation compared to baseline of 0.23 ± 0.45 mmHg, p=0.71). Outflow facility, the primary determinant of IOP, was 84% greater in NT eyes compared to PL (4.87 ± 1.09 vs. 2.64 ± 0.44 nl/min/mmHg, p=0.08, <xref ref-type="fig" rid="fig2">Figure 2C</xref>). Long-term treatment with NT appeared to impact outflow facility in both treated and contralateral eyes (4.87 vs. 4.39 nl/min/mmHg, respectively), likely due to contralateral effects as observed previously with DEX (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Netarsudil (NT) prevented and reversed steroid-induced ocular hypertension by improving outflow function.</title><p>(<bold>A</bold>) In the prevention study, intraocular pressure (IOP) was measured in two groups of age- and gender-matched wild-type C57BL/6 mice receiving NT or placebo (PL) unilaterally by subconjunctival injections. The day after NT/PL treatment was started, dexamethasone-loaded nanoparticles (DEX-NPs) were delivered bilaterally into the periocular space to release DEX and create steroid ocular hypertension. We continued to apply NT or PL 2–3 times per week to the same eye and to deliver DEX-NPs 1–2 times per week bilaterally for 4 weeks. (<bold>B</bold>) The IOP data over time are displayed as mean ± SD (n = 8 for each group). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 comparing NT vs. PL groups. (<bold>C</bold>) We summarize the data from Panel B by showing the average IOP elevation over baseline (‘delta IOP’) following NT or PL treatment in the presence of continuous DEX-NP delivery. ‘Before DEX-NP’ refers to IOP elevations at 1 day post-NT or -PL treatment but before delivery of DEX-NPs, and ‘during DEX-NP’ refers to IOP elevations averaged over 4–28 days of NT or PL treatment, i.e., over 3–27 days of DEX-NP delivery. ***p&lt;0.001 comparing NT vs. PL groups. (<bold>D</bold>) After 4 weeks of PL or NT treatment, outflow facility was measured in freshly enucleated eyes (p=0.08 for comparison of DEX-NP+PL vs. DEX-NP+NT, n = 7–9). Brackets indicate paired eyes. (<bold>E</bold>) In the second (reversal) study, IOP was measured in two groups of age- and gender-matched mice receiving DEX-NPs bilaterally 1–2 times per week for 3 weeks. During the last 5 days, NT or PL was administered unilaterally and DEX ointment bilaterally, once per day for four consecutive days. (<bold>F</bold>) We found that NT rapidly reversed three weeks of DEX-NP-induced ocular hypertension. The data show mean ± SD (n = 17 for PL group and n = 19 for NT group). **p&lt;0.01, ***p&lt;0.001 comparing NT vs. PL groups. (<bold>G</bold>) We summarize the data from Panel F by showing average IOP elevations above baseline (‘delta IOP’) for DEX-NP-treated eyes in both groups prior to NT or PL treatment (left side) or averaged over 1–4 days of NT or PL treatment (right side). ***p&lt;0.001 comparing NT vs. PL groups. (<bold>H</bold>) On day 5 of NT/PL treatment, both eyes were enucleated and outflow facility was measured (*p=0.038, n = 9 for DEX-DP+PL and n = 11 for DEX-NP+NT group). Brackets indicate paired eyes. See <xref ref-type="fig" rid="fig1">Figure 1</xref> for interpretation of box and whisker plots. Source data for IOPs and outflow facilities in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for IOPs and outflow facilities in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Netarsudil (NT) reversed dexamethasone-loaded nanoparticle (DEX-NP)-induced intraocular pressure (IOP) elevation even after 3 months.</title><p>Two groups of age- and gender-matched wild-type C57BL/6 mice were treated unilaterally with DEX-NPs twice per month for 3 months. During the last week, eyes were treated with NT or placebo (PL) once per day for 4 days. IOP was measured at indicated time points. N = 7 animals per group. Notably, this regimen (e.g., twice per month DEX-NPs) gives a more modest IOP increase (3–4 mmHg) and differs from regimen described for the 4-week studies in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Motivated by these findings, we next tested NT’s ability to reverse steroid-induced OHT. We delivered DEX-NPs bilaterally for 3 weeks to mice <italic>before</italic> initiating unilateral NT or PL therapy (once per day for 4 consecutive days). The baseline IOPs before DEX treatment in both NT and PL groups were similar (18.5 ± 1.76 vs. 19.2 ± 1.28 mmHg, respectively, p=0.21). After 3 days of DEX-NP administration, IOP was significantly elevated in both groups (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). After 3 weeks of DEX-NP treatment, average IOP elevation (days 3–21) compared to baseline in PL and NT cohorts was similar (6.77 ± 0.67 vs. 7.74 ± 0.384 mmHg, respectively, p=0.45, <xref ref-type="fig" rid="fig2">Figure 2E</xref>). Commencement of NT treatment resulted in rapid IOP lowering (within 1 day) followed by a continued decrease. After 4 days of treatment, the change in IOP from baseline in PL-treated eyes was 8.19 ± 0.46 vs. 2.69 ± 0.47 mmHg for NT-treated eyes (p&lt;10<sup>−4</sup>). In fact, NT almost completely reversed steroid-induced OHT, returning IOP to near baseline levels (18.5 ± 1.76 vs. 21.4 ± 1.30 mmHg). NT increased outflow facility by 33% compared to PL (5.18 ± 0.57 vs. 3.48 ± 0.51 nl/min/mmHg, p=0.038, <xref ref-type="fig" rid="fig2">Figure 2F</xref>) and increased outflow by 37% compared to contralateral eyes (3.27 ± 0.49 nl/min/mmHg, p=0.025). Assuming no effect of NT on aqueous inflow rate, these measured facility differences can mathematically account for 93–102% of the observed IOP differences between NT- and PL-treated eyes, both here and in the prevention study. If a 10–15% reduction of aqueous inflow is accounted for, the measured facility differences account for 85–95% of the observed IOP changes. We conclude that NT’s IOP-lowering effect in this steroid glaucoma model can be largely explained by increased outflow facility.</p></sec><sec id="s2-3"><title>Reduction of steroid-induced TM stiffening by NT</title><p>Mechanical stiffness of the TM, a key tissue in the conventional outflow pathway, was shown to be increased by GC treatment, negatively correlating with outflow facility (<xref ref-type="bibr" rid="bib77">Wang et al., 2018</xref>). We also previously showed that GC treatment decreased the tendency of the Schlemm’s canal (SC) lumen to collapse at elevated IOPs (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>), an effect that appeared to be mediated by changes in TM stiffness. Since ROCKi such as NT decrease cellular contractility and act as anti-fibrotic agents (<xref ref-type="bibr" rid="bib38">Lin et al., 2018</xref>), we hypothesized that NT would reverse steroid-induced conventional outflow tissue stiffening and lead to more SC collapse at elevated IOPs. To test this hypothesis, we used our reversal protocol as above. On day 5 after the last NT/PL treatment, mice were anesthetized and secured on a custom imaging platform (<xref ref-type="bibr" rid="bib33">Li et al., 2014a</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2014b</xref>; <xref ref-type="bibr" rid="bib5">Boussommier-Calleja et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). The anterior chamber of the NT- or PL-treated eye was cannulated with a single needle connected to a fluid reservoir, allowing IOP to be controlled. The conventional outflow tissues were imaged using optical coherence tomography (OCT) as IOP was clamped at five different levels. With increasing IOP, the SC lumen became smaller in both NT- and PL-treated eyes, but to different extents. In PL-treated eyes, the SC lumen was still patent at an IOP of 20 mmHg, while the SC lumen in NT-treated eyes was almost completely collapsed. In fact, the SC luminal cross-sectional areas differed significantly between NT- and PL-treated groups at each pressure level (p=0.0024, <xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Netarsudil (NT) reduced steroid-induced trabecular meshwork (TM) stiffening visualized in living mice by spectral domain-optical coherence tomography (SD-OCT) and estimated by inverse finite element modeling (iFEM) and measured directly by atomic force microscopy (AFM).</title><p>Wild-type C57BL/6 mice received dexamethasone-loaded nanoparticles (DEX-NPs) bilaterally for 4 weeks. During the last week, mice received either NT or placebo (PL) unilaterally for 4 consecutive days. (<bold>A–F</bold>) On day 5, living mouse eyes were cannulated to control intraocular pressure (IOP) and were subjected to sequentially increasing pressure steps (10–20 mmHg) while imaging conventional outflow tissues using OCT. Images were analyzed and Schlemm’s canal (SC) lumen semi-automatically segmented (in blue) using custom SchlemmSeg software (<bold>A’–F’</bold>). The increased tendency toward SC collapse in NT- vs. PL-treated eyes is evident. (<bold>G</bold>) Quantitative comparison of SC lumen areas (blue regions in Panels <bold>A’-F’</bold>) in both NT and PL treatment group at five clamped IOPs (10, 12, 15, 17, and 20 mmHg). The plotted quantity is relative SC area (normalized to value at 10 mmHg), and the data show an increased tendency toward SC collapse in NT-treated eyes compared to PL-treated eyes. The dots indicate individual eyes, and bars represent mean values for each IOP. Shaded regions indicate 95% confidence intervals. N = 6 for PL and n = 8 for NT treatment groups. We conducted iFEM to structurally analyze the response of anterior segment tissues to varying IOP levels, mimicking the experimental measurements. Dashed lines show results of the iFEM analysis for least squares best fit TM stiffness values, yielding estimated stiffnesses of 61 kPa for PL-treated eyes and 22 kPa for NT-treated eyes. Abbreviations: IR = iris. (<bold>H</bold>) At day 5, eyes were collected and processed for atomic force measurements of TM stiffness (Young’s modulus). We observed that NT softened the TM vs. control eyes. Brackets indicate paired eyes. We point out that the magnitudes of the AFM and OCT/iFEM measurements of TM stiffness differ due to the well-known dependence of soft tissue stiffness on loading mode (compression by AFM vs. tension by SC lumen pressurization) (<xref ref-type="bibr" rid="bib12">Ethier and Simmons, 2007</xref>), as discussed in more detail in <xref ref-type="bibr" rid="bib75">Wang et al., 2017a</xref>. An average of 135 measurements were made from three quadrants on four biological samples for both cohorts, p=0.007. Blue brackets indicate paired eyes. See <xref ref-type="fig" rid="fig1">Figure 1</xref> for interpretation of box and whisker plots. Source data for area of SC lumen in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. Source data for FEM in <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>. Source data for AFM measurements in <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data for segmentation of area of SC lumen in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Source data for FEM in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig3-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Source data for AFM measurements in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Netarsudil (NT) enhanced intraocular pressure (IOP)-induced collapse of Schlemm’s canal (SC) lumen in ocular hypertensive eyes as visualized by spectral domain-optical coherence tomography (SD-OCT).</title><p>Mice were treated with dexamethasone-loaded nanoparticles (DEX-NPs) in both eyes for 4 weeks and unilaterally with NT or placebo (PL) for 4 consecutive days. On day 5, living mouse eyes were cannulated to control IOP and were subjected to sequentially increasing pressure steps to create IOPs of 10, 12, 15, 17, and 20 mmHg. OCT imaging of conventional outflow tissues was conducted in both NT- and PL-treated eyes, and the images were averaged to reduce noise at each pressure step. (<bold>A</bold>) Shows NT-treated eyes, while C) shows PL-treated eyes. Corresponding images (<bold>A’, C’</bold>) Show SC lumen segmentation by SchlemmSeg software with lumens indicated in blue. Panels B, B’, D, and D’ show the corresponding speckle variance images and SC segmentations. TM, trabecular meshwork; IR, iris.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Quantitative comparison of normalized Schlemm’s canal (SC) lumen areas in netarsudil (NT) and placebo (PL) treatment groups at five clamped intraocular pressures (IOPs) (10, 12, 15, 17, and 20 mmHg).</title><p>This figure is similar to <xref ref-type="fig" rid="fig3">Figure 3G</xref>, but also includes results from eyes with dexamethasone-loaded nanoparticle (DEX-NP) treatment without administration of either NT or PL (DEX-NP, red) and from control eyes that received no glucocorticoids (CONT-NP, green), both adopted from our previous study (<xref ref-type="bibr" rid="bib44">McMurtry et al., 2010</xref>). The plotted quantity is relative SC area (normalized to value at 10 mmHg) and the bars represent mean values for each IOP. We conducted inverse finite element modeling (iFEM) to structurally analyze the response of anterior segment tissues to varying IOP levels, mimicking the experimental measurements. Dashed lines show results of the iFEM analysis for least squares best fit trabecular meshwork (TM) stiffness values, yielding estimated stiffnesses of 61 kPa for PL-treated DEX-NP eyes, 22 kPa for NT-treated DEX-NP eyes, 69 kPa for eyes receiving only DEX-NPs, and 29 kPa for eyes receiving CONT-NPs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>A representative cryosection showing the limbal region during AFM measurements of TM stiffness, acquired on a tissue sample immersed in PBS.</title><p>AFM, atomic force microscopy; PBS, phosphate buffered saline; SC, Schlemm’s canal; TM, trabecular meshwork. Section thickness 10 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig3-figsupp3-v1.tif"/></fig></fig-group><p>We next quantified NT effects on TM stiffness using inverse finite element modeling (iFEM) (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>) based on the OCT images acquired in vivo. This iFEM procedure, allowing us to deduce TM stiffness based on structural analysis of SC collapse and associated TM deformation, was performed on OCT images from both NT- and PL-treated groups. We deduced TM tissue stiffness values of 22 kPa in the NT-treated group vs. 61 kPa in the PL-treated group (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). The latter value is consistent with the TM stiffness we previously measured in DEX-NP treated eyes of 69 kPa (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Notably, the TM stiffness we estimated in NT-treated eyes was close to the value of 29 kPa that we previously determined in naïve eyes (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Thus, it appears that NT returns TM stiffness to near control levels after only 4 days of administration in eyes made hypertensive by long-term GC administration.</p><p>It was desirable to obtain an independent and direct measurement of TM stiffness in a cohort of NT-treated mouse eyes. For this purpose, we used atomic force microscopy (AFM) (<xref ref-type="bibr" rid="bib76">Wang et al., 2017b</xref>; <xref ref-type="bibr" rid="bib77">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Using the reversal treatment protocol, we observed that NT significantly reduced TM tissue stiffness by 23% compared to contralateral eyes (1.54 ± 0.19 vs. 2.00 ± 0.13 kPa, p=0.007, <xref ref-type="fig" rid="fig3">Figure 3H</xref>). In contrast, PL did not affect TM tissue stiffness compared to contralateral eyes (1.39 ± 0.12 vs. 1.73 ± 0.20 kPa, p=0.39). When stiffness measurements of PL and NT groups were normalized to untreated contralateral eyes, a trend toward NT-induced softening was observed but was not significant perhaps due to small sample size (p=0.15).</p></sec><sec id="s2-4"><title>Anti-fibrotic activity of NT in GC-treated conventional outflow tissues</title><p>We next investigated NT effects on fibrotic and morphological changes in TM tissues. At the light microscopic level, we observed no gross morphological changes in conventional outflow tissues in NT- vs. PL-treated steroid-induced OHT eyes (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). In contrast, we observed that NT treatment reduced the expression of alpha smooth muscle actin (αSMA; <xref ref-type="fig" rid="fig4">Figure 4H</xref> vs. 4I) and fibronectin (FN; <xref ref-type="fig" rid="fig4">Figure 4E</xref> vs. 4F), two fibrotic indicators known to be elevated in conventional outflow tissues after GC treatment. Mean fluorescence intensities from the TM region of sections in PL vs. NT treatment groups were quantified in a masked fashion (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for an example). Results indicate that NT treatment significantly reduced both αSMA (4K, p=0.037) and FN protein expression (4J, p=0.007). In fact, NT-mediated down-regulation led to αSMA and FN levels similar to those observed previously in eyes treated with phosphate buffered saline (PBS)-loaded (sham) NPs (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>) and naïve eyes (4D and 4G).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Netarsudil (NT) decreased fibrotic markers in ocular hypertensive mouse eyes.</title><p>Two groups of age- and gender-matched wild-type C57BL/6 mice had dexamethasone-loaded nanoparticles (DEX-NPs) delivered bilaterally 1–2 times per week for 4 weeks to create ocular hypertension. During the last week of DEX-NP exposure, mice were split into two subgroups and treated unilaterally with either NT or placebo (PL) once per day for 4 consecutive days. At day 5, eyes were collected and processed for histological analysis and compared to untreated control eyes. (<bold>A–C</bold>) Representative sagittal sections of iridocorneal tissues visualized by light microscopy after methylene blue staining, showing normal gross morphology in NT-treated eyes. Boxes in A–C indicate areas of interest displayed in Panels D–I. Control, PL- or NT-treated ocular hypertensive eyes were sectioned and iridocorneal tissues were probed with antibodies recognizing fibronectin (FN) (<bold>D–F</bold>) or alpha-smooth muscle actin (αSMA; <bold>G–I</bold>). Identical confocal settings were used for all samples, which were imaged on the same day. Data shown are representative of samples from 10 images from seven control mice, and 10 images from five mice treated with NT or PL. Nuclei were counterstained with DAPI in (<bold>C–F</bold>). Asterisks indicate Schlemm’s canal (SC) lumen, arrowheads show trabecular meshwork. (<bold>J, K</bold>) Fluorescence intensity from the trabecular meshwork region of each image was quantified in a masked fashion (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) as summarized in box and whisker plots. Data show average fluorescence intensity measurements of trabecular meshwork (TM) from different sections of eyes under different treatment conditions. See <xref ref-type="fig" rid="fig1">Figure 1</xref> for interpretation of box and whisker plots. n = 5 eyes for PL- and NT-treated eyes, n = 7 for untreated eyes (CON). *p&lt;0.05 and **p&lt;0.01. Source data for quantification of FN and αSMA fluorescence in TM in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>, respectively.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for quantification of FN in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Source dat for quantification of SMA in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig4-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Quantitative analysis of fibronectin (FN) and alpha-smooth muscle actin (αSMA) expression in trabecular meshwork (TM).</title><p>Wild-type C57BL/6 mice were injected subconjunctivally/periorbitally with dexamethasone-loaded nanoparticles (DEX-NPs), delivered bilaterally 1–2 times per week for 3 weeks to induce ocular hypertension, followed by DEX ophthalmic ointment once per day for 4 days. During the last 4 days of DEX-NP exposure, mice were split into two subgroups and treated unilaterally with either netarsudil (NT) or placebo (PL) once per day for 4 consecutive days. At day 5, eyes were collected, sectioned, and iridocorneal tissues were probed with antibodies recognizing FN or αSMA. Fluorescent secondary antibody binding was visualized under identical confocal microscopic settings between experimental and control groups. Using ImageJ software, the TM from each image was manually delineated and fluorescence within the TM was quantified in a masked fashion. Representative images show marking of TM region in sections labeled with antibodies specific for FN (panels A and A’) and αSMA (panels B and B’). Panels C and D show companion images from sequential sections where primary antibodies were omitted. Panels E and F show summaries of fluorescent intensity in the TM region (averaged for each analyzed eye) under different conditions and are displayed in a box and whisker plot. <xref ref-type="fig" rid="fig4">Figure 4</xref> shows a similar plot where average fluorescent intensity is shown for each section. See <xref ref-type="fig" rid="fig1">Figure 1</xref> for interpretation of the box and whisker plots. CON indicates untreated naïve eyes. *p&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig4-figsupp1-v1.tif"/></fig></fig-group><p>When examined at the electron microscopic level, we observed two major effects of NT treatment on steroid-induced OHT eyes (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The first was a significant reduction in the amount and density of basement membrane materials (BMM) underlying the inner wall of SC. The second was an apparent increase in the number of ‘open spaces’ in the TM of NT-treated eyes, particularly in the juxtacanalicular (JCT) region. These two changes were scored on a semi-quantitative scale, confirming observational impressions of NT treatment (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, p=0.02). In addition, we quantified the amount of BMM below the inner wall of SC in each treatment group following the Lütjen-Drecoll approach (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib52">Overby et al., 2014</xref>). Similar to results reported in Overby et al., we found that length of BMM underlying SC was significantly increased in mice after DEX treatment (<xref ref-type="fig" rid="fig5">Figure 5G</xref>, p&lt;0.001). Indeed, our BMM ratio measurements in control and DEX-treated mice were quantitatively similar to those reported by Overby and colleagues. Most importantly, these data confirm significant differences between PL- and NT-treated eyes (<xref ref-type="fig" rid="fig5">Figure 5G</xref>, p=0.001), whereby NT appears to partially restore the ultrastructure of the subendothelial region.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Netarsudil (NT) partially normalized ultrastructure of conventional outflow tissues in ocular hypertensive eyes.</title><p>Two groups of age- and gender-matched wild-type C57BL/6 mice were bilaterally treated with dexamethasone-loaded nanoparticles (DEX-NPs) 1–2 times per week for 4 weeks. During the last week of DEX-NPs exposure, one group of mice was unilaterally treated with NT and another group with placebo (PL) once per day for 4 consecutive days. At day 5, eyes were collected and fixed with 4% PFA plus 1% glutaraldehyde in phosphate buffered saline (PBS) for 1–3 days at 4°C. The anterior segments were embedded in Epon, sectioned, stained with uranyl acetate/lead citrate, and examined with a JEM-1400 electron microscope. We show representative images from (<bold>A</bold>) five eyes naïve to NPs or treatment, (<bold>B</bold>) five control eyes (injected with NPs not loaded with DEX [Ghost-NP]), (<bold>C</bold>) five DEX-NP treated eyes, (<bold>D</bold>) 11 PL-treated eyes, and (<bold>E</bold>) nine NT-treated eyes. (<bold>A’–E’</bold>) show enlarged areas indicated by boxes in (<bold>A–E</bold>). Arrowheads point to basement membrane materials (BMM) underlying Schlemm’s canal (SC) inner wall endothelial cells. (<bold>F</bold>) Summary of results from semi-quantitative scoring of extracellular matrix (ECM) in juxtacanalicular (JCT) region, paying particular attention to ECM underlying SC endothelial cells. Images in Panels A and B were scored as ‘0’ (normal appearance), while the image in Panel C was scored as ‘2’ (continuous and extensive ECM below SC and ECM in JCT). Shown are mean values for each eye, corresponding to 10, 13, 18, 12, and 8 images in each group that were graded. **p&lt;0.01 comparing Ghost-NP vs. DEX-NP; *p&lt;0.05 comparing DEX-NP+PL vs. DEX-NP+NT. The empty symbol was statistically determined to be an outlier of the DEX-NP+NT data set. (<bold>G</bold>) Summary of results from quantifying the amount of BMM underlying the inner wall of SC. The BMM ratio was calculated by measuring the length of the BMM underlying the SC inner wall and dividing the value by the SC inner wall’s total length (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Shown are mean values for each eye taken from 8, 10, 12, 34, and 33 images in each group. **p&lt;0.01 comparing Ghost-NP vs. DEX-NP or DEX-NP+PL vs. DEX-NP+NT. Source data for semi-quantitative scoring of JCT and quantitative measurements of BMM in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>, respectively.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for semi-quantitative scoring of JCT in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Source data for quantitative measurements of BMM in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60831-fig5-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Quantification of basement membrane material (BMM) underlying the inner wall of Schlemm’s canal.</title><p>Shown is a representative example of the quantification approach that was performed on 97 images. The lengths of the continuous BMM (in red) and the total length of the inner wall (in blue) were measured using ImageJ software, and the sum of the continuous BMM length was divided by the total inner wall length. Only continuous BMM in contact with the inner wall was included. Ratios from multiple images from the same eye were averaged to produce a single value per eye. Asterisks: regions where BMM material was not included in the quantification due to separation of BMM from inner wall.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig5-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The major finding of the current study was that NT effectively decreased steroid-induced OHT in two different cohorts of patients who were refractory to standard glaucoma medications. This clinical observation was mechanistically studied in a reliable, established mouse model of steroid-induced OHT (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). As in patients, NT decreased long-term steroid-induced OHT in mice and also prevented the onset of steroid-induced OHT. NT-mediated rescue of OHT in mice was accompanied by restoration of normal outflow facility and conventional outflow tissue stiffness, as well as significant morphological alterations in the TM. Calculations suggest that the IOP effect seen in NT-treated mice was mostly or entirely explainable by changes in outflow facility, which together with our direct and indirect measurements of TM stiffness implicate the TM as the tissue mediating the effects of NT on IOP. Thus, this is the first demonstration of prevention and rescue from steroid-induced OHT by a ‘TM-active’ FDA-approved glaucoma medication and suggests that ROCKi compounds have effective anti-fibrotic activity in the TM.</p><p>Our results extend findings from an earlier report showing that a ROCKi lowered IOP in a transgenic mouse locally overexpressing connective tissue growth factor (CTGF) (<xref ref-type="bibr" rid="bib26">Junglas et al., 2012</xref>), to a clinically relevant disease context by demonstrating NT activity in the conventional outflow pathway. Importantly, two significant phenotypic changes were observed in NT-treated eyes with OHT. The first was a rapid reversal of IOP elevation (within 1–2 days). The second was a significant decrease in accumulated ECM materials, namely FN and basal lamina material underlying the inner wall of SC. Both cellular contractility changes and ECM changes likely contribute to the observed decrease of TM tissue stiffness by NT. In addition to NT-mediated changes in ECM turnover, the observed changes in ECM composition and amount may also be due to NT-mediated opening of flow pathways and consequential removal of ECM. In any case, having a therapy for steroid-induced OHT that inhibits the cycle of fibrosis by restoring function to a diseased tissue offers a potential benefit for patients (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Schematic representation of a feed-forward model of fibrotic disease in the conventional outflow pathway responsible for ocular hypertension, incorporating a number of pathophysiological aspects of ocular hypertension (<xref ref-type="bibr" rid="bib66">Stamer and Acott, 2012</xref>, <xref ref-type="bibr" rid="bib62">Schmidl et al., 2015</xref>).</title><p>The broader literature suggests that this feed-forward loop can be triggered by multiple factors, including aging, oxidative stress, or genetic predisposition. In this work we triggered this loop by corticosteroid administration and restored tissue function through rho-kinase inhibition. TM, trabecular meshwork.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60831-fig6-v1.tif"/></fig><p>Evidence shows that the biomechanical properties of TM tissue play an important role in the regulation of outflow function and thus IOP (<xref ref-type="bibr" rid="bib75">Wang et al., 2017a</xref>; <xref ref-type="bibr" rid="bib77">Wang et al., 2018</xref>). For example, alterations in the biomechanical properties (i.e., stiffening) of the TM are observed in glaucomatous human donor eyes, which were hypothesized to be associated with dysregulation of the ECM (<xref ref-type="bibr" rid="bib40">Lütjen-Drecoll et al., 1986</xref>; <xref ref-type="bibr" rid="bib80">Yue, 1996</xref>; <xref ref-type="bibr" rid="bib70">Tamm and Fuchshofer, 2007</xref>; <xref ref-type="bibr" rid="bib28">Keller et al., 2009</xref>; <xref ref-type="bibr" rid="bib73">Tektas and Lütjen-Drecoll, 2009</xref>; <xref ref-type="bibr" rid="bib32">Last et al., 2011</xref>). TM stiffening and elevated IOP were also observed in animal models of steroid-induced OHT (<xref ref-type="bibr" rid="bib56">Raghunathan et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). In a recent study, we showed that TM tissue stiffness is associated with increased outflow resistance in steroid-induced OHT mouse eyes (<xref ref-type="bibr" rid="bib77">Wang et al., 2018</xref>). We consider it noteworthy that NT appears to have restored normal TM biomechanical properties in our steroid-induced OHT model after only 4 days of treatment, and that this restoration was accompanied by significant morphological changes in the ECM of the TM. These in vivo observations in a relevant disease model confirm the importance of the rho-kinase pathway, and more generally the importance of cellular biomechanical tension as mediated through actomyosin cytoskeletal tension, on ECM synthesis, assembly, and degradation (<xref ref-type="bibr" rid="bib57">Rao et al., 2001</xref>; <xref ref-type="bibr" rid="bib49">Nakajima et al., 2005</xref>; <xref ref-type="bibr" rid="bib53">Pattabiraman and Rao, 2010</xref>). The rapid timescale of the observed ECM changes is consistent with observations from postmortem human eye preparations (<xref ref-type="bibr" rid="bib28">Keller et al., 2009</xref>). The time course of structural changes in the TM was also consistent with the observed rapid (within 24 hr) pharmacodynamics of NT on IOP, significantly decreasing 1 and 3 months of OHT due to DEX treatment (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, respectively). This time course is consistent with known effects of ROCKis (<xref ref-type="bibr" rid="bib44">McMurtry et al., 2010</xref>; <xref ref-type="bibr" rid="bib38">Lin et al., 2018</xref>).</p><p>More generally, these data emphasize the anti-fibrotic properties of ROCKi in the conventional outflow pathway, consistent with a large body of literature in other tissues. Many mechanisms have been proposed for the systemically delivered anti-fibrotic effects of ROCKi, including inhibition of monocyte differentiation in a murine model of ischemic/reperfusion cardiomyopathy (<xref ref-type="bibr" rid="bib16">Haudek et al., 2009</xref>), and macrophage infiltration of injured tissues in mouse models of multiple fibrotic diseases, including renal tubulointerstitial fibrosis, diabetic nephropathy, renal allograft rejection, peritoneal fibrosis, and atherosclerosis (<xref ref-type="bibr" rid="bib78">Wu et al., 2009</xref>; <xref ref-type="bibr" rid="bib29">Knipe et al., 2015</xref>). In view of the eye’s immune-privileged status and local delivery of NT in the present study, it seems likely that resident cells of the conventional outflow pathway primarily mediate NT effects. In other tissues, RKIs inhibit TGF-β1-induced activation of p38 MAPK (<xref ref-type="bibr" rid="bib19">Holvoet et al., 2017</xref>), activation of myocardin-related transcription factors (MRTFs), known to be master regulators of epithelial-mesenchymal transition (<xref ref-type="bibr" rid="bib14">Gasparics and Sebe, 2018</xref>), and reduced activation of NF-κB (<xref ref-type="bibr" rid="bib63">Segain et al., 2003</xref>). Importantly, downstream targets of MRTFs include CTGF and YAP/TAZ, and TGF-β-mediated signaling through p38 and NF-κB (<xref ref-type="bibr" rid="bib55">Raghunathan et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Braunger et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">Inoue-Mochita et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Tamm et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Montecchi-Palmer et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Hernandez et al., 2020</xref>), all of which participate in the regulation of TM contractility, mechanotransduction, and IOP homeostasis. Thus, our DEX-induced OHT model represents a tool for further interrogation of these pathways in the context of an immune-privileged environment (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>We used two complementary methods to estimate conventional outflow tissue stiffness, and each has advantages and disadvantages. AFM was used to directly measure the compressive mechanical properties of the conventional outflow tissues in mouse eyes at different locations of the TM and around the eye with high resolution (<xref ref-type="bibr" rid="bib72">Tao et al., 1992</xref>; <xref ref-type="bibr" rid="bib1">A-Hassan et al., 1998</xref>; <xref ref-type="bibr" rid="bib43">Matzke et al., 2001</xref>; <xref ref-type="bibr" rid="bib76">Wang et al., 2017b</xref>). However, AFM measurements of stiffness could only be conducted ex vivo on ‘dead’ tissues using a cryosectioning technique coupled with AFM. Thus, these measurements likely reflect the stiffness of the ECM, not cells (<xref ref-type="bibr" rid="bib76">Wang et al., 2017b</xref>). In contrast, tensile stiffness estimates of conventional outflow tissues were derived from changes in area of SC lumen in living mouse eyes exposed to sequential IOP challenges. TM behavior was captured using spectral domain (SD)-OCT, and stiffness was then quantified by iFEM as described previously (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). The disadvantage with OCT is that eyes are imaged at only one location. Regardless, both methods showed consistent results, that is, that NT significantly reduced steroid-induced conventional outflow tissue stiffness. While desirable, technical concerns prevented OCT, AFM, and outflow facility measurements in the same eye.</p><p>Before the approval of NT in December 2017, four classes of glaucoma drugs (beta-adrenergic receptor antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and/or prostaglandin analogues) were used to treat steroid-induced OHT. Unfortunately, none of these drugs directly target tissues responsible for homeostatic regulation of IOP in healthy eyes nor for the dysregulation of IOP in steroid-induced glaucoma. Instead, these drugs either decrease aqueous humor formation or divert aqueous humor from the conventional outflow pathway by increasing unconventional outflow drainage (<xref ref-type="bibr" rid="bib9">Bucolo et al., 2015</xref>; <xref ref-type="bibr" rid="bib62">Schmidl et al., 2015</xref>). Despite modest effects on conventional outflow (<xref ref-type="bibr" rid="bib7">Brubaker et al., 2001</xref>; <xref ref-type="bibr" rid="bib74">Wan et al., 2007</xref>; <xref ref-type="bibr" rid="bib3">Bahler et al., 2008</xref>), prostaglandins are not often used to treat steroid-induced OHT due to concern about their effects on the blood-retinal barrier in vulnerable retinas (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="bibr" rid="bib47">Moroi et al., 1999</xref>). NT was the first agent to selectively target and modify conventional outflow morphology and function (<xref ref-type="bibr" rid="bib35">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Ren et al., 2016</xref>). However, the current standard of care is for patients to be first treated with glaucoma medications that do not target the conventional outflow pathway, with NT being used only when these drugs are ineffective at IOP lowering. In two independent patient populations, we found 27 patients that had steroid-induced OHT and were treated with NT. Despite being first treated with multiple first- and second-line glaucoma medications (mean of 2.7 and 2.4), NT lowered IOP by an average of 7.9 mmHg in the first cohort and 6.0 mmHg in the second. These observations are consistent with mechanistic data from our mouse model, supporting the concept that the TM is the location of pathology in steroid-induced OHT, and emphasizing the importance of targeting the conventional outflow pathway in this well-recognized condition.</p><p>While patient data were encouraging, there were limitations to our approach. We used a retrospective chart review involving few patients that were treated with NT as a last resort by some, but not all physicians. Thus there was not a control group to determine how many patients were effectively managed on first- and/or second-line medications. These limitations along with the new data presented herein motivate the need for a randomized prospective clinical study to compare NT with first-line anti-glaucoma drugs in lowering steroid-induced OHT.</p><p>Steroid-induced OHT in mice was generated using nanotechnology (<xref ref-type="bibr" rid="bib2">Agrahari et al., 2017</xref>), resulting in a model that closely matched steroid-induced observations in the human condition (decreased outflow facility, increased accumulation of ECM in the TM, and elevated IOP) (<xref ref-type="bibr" rid="bib23">Johnson et al., 1990</xref>; <xref ref-type="bibr" rid="bib25">Johnson and Knepper, 1994</xref>; <xref ref-type="bibr" rid="bib24">Johnson et al., 1997</xref>; <xref ref-type="bibr" rid="bib10">Clark et al., 2001</xref>). The present study suggests the utility of our mouse model of steroid-induced OHT and its translational relevance to the human clinical condition, where there is a high incidence of OHT in patients receiving intravitreal GC delivery implants to treat uveitis or macular edema. Our data indicate that human steroid-induced OHT patients who are refractory to standard glaucoma medications respond very well to NT. This retrospective study encourages a prospective study testing NT as a first-line drug for steroid-induced OHT. Further, our study utilizes methodology for non-contact, non-invasive estimation of conventional outflow function/health using OCT and iFEM. Our results confirm that this technology may have the resolution to detect changes in conventional outflow dysfunction due to GC treatment and restoration of function after drug treatment. In clinical practice, we suggest that this technology may have potential utility in staging glaucoma status and in monitoring treatment.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Software, algorithm</td><td>Schlemm3_2</td><td>PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/30651311">30651311</ext-link></td><td>Version 3.0</td><td>Schlemm’s canal segmentation</td></tr><tr><td>Software, algorithm</td><td>FEBio</td><td><ext-link ext-link-type="uri" xlink:href="https://febio.org/">https://febio.org/</ext-link></td><td>Version 3.0</td><td>Finite element modeling</td></tr><tr><td>Antibody</td><td>Anti-αSMA (rabbit polyclonal)</td><td>Abcam, Cambridge, MA</td><td>ab5694</td><td>IF (1:100)</td></tr><tr><td>Antibody</td><td>Anti-FN (mouse monoclonal)</td><td>Santa Cruz, Dallas, TX</td><td>sc8422</td><td>IF (1:50)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Study design</title><p>Experiments were designed to test the hypothesis that dysregulation of conventional outflow function caused by GCs can be mitigated by NT treatment. The hypothesis was tested using a retrospective review of patients who were refractory to standard glaucoma treatments and in a validated mouse model of steroid-induced OHT that we developed (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>).</p><p>Data from humans were obtained using an unbiased retrospective analysis of electronic medical records of all patients seen by ophthalmologists at Duke Eye Center and from a retrospective chart review of two private clinical practices. All steroid-induced glaucoma patients treated with NT were included if not complicated with secondary diagnosis as detailed below. IOPs from one patient were excluded from the data set because they were greater than 1.5 times a quartile different from 75th percentile.</p><p>Mouse studies were based on sustained subconjunctival/periocular delivery of steroid to induce OHT (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Cohort sizes were determined using power analysis of data generated previously with this model (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>) and treatment effects with NT (<xref ref-type="bibr" rid="bib35">Li et al., 2016</xref>). Eyes of mice were randomized to receive either NT or PL, and experimentalists were masked to treatment type. Primary endpoints (IOP, outflow facility, Young’s modulus of TM, outflow tissue behavior visualized by OCT following IOP challenges, outflow tissue morphology by transmission electron microscope [TEM], and fibrotic marker expression by IHC) were established prior to start of experiments and all data were included in the analyses.</p></sec><sec id="s4-2"><title>Patient ascertainment, IOP measurement, and treatment</title><p>We identified two cohorts of patients with steroid-induced OHT who had been treated with NT. The first cohort was drawn from patients seen at the Duke Eye Center, using IRB-approved access to patient data via the EPIC electronic medical record system using SlicerDicer software. Search criteria included ‘netarsudil’ and associated ICD-10 codes for ‘steroid responder’ and ‘steroid glaucoma’ (H40.041, H40.042, H40.043, T38.0 × 5A, H40.60 × 0, H40.61 × 0, H40.62 × 0, and H40.63 × 0) between January 1, 2018, and March 1, 2020. Twenty-one eyes of 19 patients were identified as having started NT due to steroid-associated IOP elevation. None of the patients were ‘tapered’ from their steroid during the first month of treatment.</p><p>The second cohort was based on a comprehensive retrospective chart review of patients seen by Dr. John Samples at two different clinic sites: The Eye Clinic in Portland, Oregon, and Olympia Eye Clinic in Olympia, Washington. Charts of all patients seen by Dr. Samples between November 3 and December 1, 2019, were reviewed. Patients were included in the study that: (1) had a diagnosis of steroid-induced glaucoma, (2) were uncontrolled on standard glaucoma medications, (3) were treated with NT, and (4) had no confounding diagnoses (exfoliation glaucoma, pigmentary glaucoma, active neovascularization, narrow/closed angles, previous glaucoma surgery).</p><p>IOP in both studies was measured by Goldmann applanation tonometry before starting NT and then within 1 month after QD NT treatment.</p></sec><sec id="s4-3"><title>Animals</title><p>C57BL/6 (C57) mice (both males and females, ages from 3 to 6 months) were used in the current study. The animals were handled in accordance with approved protocols (A020-16-02 and A001-19-01, Institutional Animal Care and Use Committee of Duke University) and in compliance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. The mice were purchased from the Jackson Laboratory (Bar Harbor, ME), bred/housed in clear cages and kept in housing rooms at 21°C with a 12 hr:12 hr light:dark cycle.</p></sec><sec id="s4-4"><title>OHT animal model</title><p>OHT in mice was created by injection of NPs entrapping dexamethasone (DEX-NPs) into either the subconjunctival or periocular spaces as described in previous publications (<xref ref-type="bibr" rid="bib77">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Briefly, DEX-NPs were diluted in PBS to a final NP concentration of 50 µg/µl, vortexed for 10 min, and then sonicated for 10 min. Mice were anesthetized with 100 mg/10 mg/kg of ketamine/xylazine. 20 µl per eye of the DEX-NP suspension (containing 1 mg of NPs with ~23 µg of DEX) was slowly injected bilaterally into either the superior or inferior subconjunctival or periocular spaces using a 30-gauge needle with a Hamilton glass microsyringe (50 µl volume; Hamilton Company, Reno, NV). After withdrawing the needle, Neomycin plus Polymyxin B Sulfate antibiotic ointment was applied to the eye and mice recovered on a warm pad. The injection was conducted 1–2 times per week for 3–4 weeks. For the last 4 days of the reversal study, DEX ophthalmic ointment (0.1%, Sandox Inc Cat# NDC 61314-631-36) was applied topically to both eyes once a day. For DEX-NP control treatment, nanoparticles without DEX (Ghost-NP) were used to treat mice in the same way.</p></sec><sec id="s4-5"><title>Drug treatments</title><p>NT and PL eye drops were provided in de-identified dropper bottles by Aerie Pharmaceuticals, Inc. All mice received bilateral treatments of DEX-NP but were randomized as to whether they were given NT or PL. In the prevention study, mice were treated unilaterally with 0.04% NT or PL by subconjunctival injection of 10 µl of NT or PL 1 day prior to bilateral DEX-NP treatment as described above, followed by NT or PL delivery 2–3 times per week for the entire 4-week duration of DEX-NP delivery. In the reversal study, eyes received DEX-NPs bilaterally 1–2 times per week for 3 weeks, followed by an additional 4 days when DEX was given once per day as topical ointment after unilateral treatment of NT or PL by subconjunctival injection (10 µl). This treatment regimen avoided potential ocular surface inflammation and animal health issues associated with multiple injections in the same eye during the last week of the study.</p></sec><sec id="s4-6"><title>IOP measurements</title><p>Mice were anesthetized with <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/topics/page/Ketamine">ketamine</ext-link> (60 mg/kg) and <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/topics/page/Xylazine">xylazine</ext-link> (6 mg/kg). IOP was measured immediately upon cessation of movement (i.e., in <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/topics/page/Non-rapid_eye_movement_sleep">light sleep</ext-link>) using rebound tonometry (TonoLab, Icare, Raleigh, NC) between 10 am and 1 pm (<xref ref-type="bibr" rid="bib33">Li et al., 2014a</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2014b</xref>; <xref ref-type="bibr" rid="bib45">Meng et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Each recorded IOP was the average of six measurements, giving a total of 36 rebounds from the same eye per recorded IOP value. IOP measurements were conducted twice per week.</p></sec><sec id="s4-7"><title>Outflow facility measurements</title><p>Outflow facility was measured by a technician (IN) who was masked as to the treatment group using the iPerfusion system as described in detail previously (<xref ref-type="bibr" rid="bib35">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Briefly, at the end of the 4 days of NT/PL treatment period in the reversal study and after 4 weeks of NT/PL treatment in the prevention study, mice were euthanized using isoflurane, and eyes were carefully enucleated and rapidly mounted on a stabilization platform located in the center of a perfusion chamber using a small amount of cyanoacrylate glue (Loctite, Westlake, OH). The perfusion chamber was filled with pre-warmed Dulbecco’s phosphate-buffered saline with added 5.5 mM D-glucose (DBG), submerging the eyes and regulating temperature at 35°C. Two glass microneedles, backfilled with filtered DBG, were connected to the system. Using micromanipulators, one microneedle was inserted into each anterior chamber of paired eyes without contacting the irises. Both eyes were perfused at 9 mmHg for 30 min to allow acclimatization and stabilization, followed by perfusion at nine sequential pressure steps of 4.5, 6, 7.5, 9, 10.5, 12, 15, 18, and 21 mmHg. Poor quality steps and subsequent pressure steps were eliminated using established criteria (<xref ref-type="bibr" rid="bib65">Sherwood et al., 2016</xref>). Stable flow rate (<italic>Q</italic>) and pressure (<italic>P</italic>) averaged over 4 min at each pressure step were used for data analysis to compute outflow facility (<xref ref-type="bibr" rid="bib45">Meng et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Sherwood et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Li et al., 2018</xref>).</p></sec><sec id="s4-8"><title>Calculations relating outflow facility changes and IOP changes</title><p>We asked whether measured IOP differences between NT and PL cohorts were quantitatively consistent with measured differences in outflow facility between these cohorts. For this purpose, we assumed that unconventional outflow rate and episcleral venous pressure were unaffected by NT, that is, were the same between NT- and PL-treated cohorts. We further assumed a 10–15% reduction in aqueous inflow rate due to NT (<xref ref-type="bibr" rid="bib27">Kazemi et al., 2018</xref>). We then used the modified Goldmann’s equation (<xref ref-type="bibr" rid="bib8">Brubaker, 2004</xref>) to determine a predicted IOP in the NT-treated eyes and compared this value to the actually measured IOP in these eyes. In brief, Goldmann’s equation states <inline-formula><mml:math id="inf1"><mml:mrow><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:mi>C</mml:mi><mml:mo> </mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>O</mml:mi><mml:mi>P</mml:mi><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>U</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="inf2"><mml:mi>Q</mml:mi></mml:math></inline-formula> is aqueous inflow rate, <inline-formula><mml:math id="inf3"><mml:mrow><mml:mi>E</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:math></inline-formula> is episcleral venous pressure, and <inline-formula><mml:math id="inf4"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mi>U</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is unconventional outflow rate. Under the stated assumptions, the predicted value of IOP in NT-treated eyes is <inline-formula><mml:math id="inf5"><mml:mrow><mml:mi>I</mml:mi><mml:mi>O</mml:mi><mml:msubsup><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi>x</mml:mi><mml:msup><mml:mi>Q</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo> </mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>O</mml:mi><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:math></inline-formula>, where superscripts indicate whether the value refers to NT- or PL-treated eyes; <inline-formula><mml:math id="inf6"><mml:mrow><mml:msup><mml:mi>Q</mml:mi><mml:mrow><mml:mi>P</mml:mi><mml:mi>L</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is the aqueous inflow rate computed from the measured IOP, measured facility, and an assumed value of <inline-formula><mml:math id="inf7"><mml:mrow><mml:mi>E</mml:mi><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:math></inline-formula>; and <inline-formula><mml:math id="inf8"><mml:mi>x</mml:mi></mml:math></inline-formula> represents the percent decrease in aqueous inflow rate due to NT, here taken as <inline-formula><mml:math id="inf9"><mml:mrow><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mo>−</mml:mo><mml:mn>15</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></inline-formula>. We assumed a range of EVP values and computed the ratio of the IOP predicted by the above formula to the actual measured IOP value in NT-treated eyes. IOP values used in the calculation were the cohort means of the last measurement taken before sacrifice, as follows: in the prevention study, 17.4 and 25.0 mmHg for NT- and PL-treated eyes, respectively, and in the reversal study, 21.0 and 28.4 mmHg for NT- and PL-treated eyes, respectively.</p></sec><sec id="s4-9"><title>Optical coherence tomographic imaging</title><p>At the end of the 4-day NT/PL treatment period in the reversal study and after 4 weeks of NT/PL treatment in the prevention study, OCT imaging was conducted in living mice. In vivo imaging utilized an Envisu R2200 high-resolution SD-OCT system (Bioptigen Inc, Research Triangle Park, NC). We followed our previously established techniques to image iridocorneal angle structures in mice (<xref ref-type="bibr" rid="bib33">Li et al., 2014a</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2014b</xref>; <xref ref-type="bibr" rid="bib5">Boussommier-Calleja et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Meng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Briefly, mice were anesthetized with ketamine (100 mg/kg)/xylazine (10 mg/kg) and maintained with ketamine (60 mg/kg) every 20 min by IP administration. While mice were secured in a custom-made platform, a single pulled glass microneedle filled with PBS was inserted into the anterior chamber of one eye. The microneedle was connected to both a manometric column to adjust IOP and a pressure transducer (Honeywell Corp., Morristown, NJ) to continuously monitor IOP levels using PowerLab software. The OCT imaging probe was aimed at the nasal or temporal limbus and the image was centered and focused on the SC lumen. While collecting images, mouse eyes were subjected to a series of IOP steps (10, 12, 15, 17, and 20 mmHg) by adjusting the height of the fluid reservoir. At each IOP step, a sequence of repeated OCT B-scans (each with 1000 A-scans spanning 0.5 mm in lateral length) from spatially close positions was captured, registered, and averaged to create a high signal-to-noise-ratio image from the iridocorneal angle region of each animal. The duration of each pressure step was ~1–2 min. Note that the cohort of mice used for OCT imaging was different than that used for facility measurement.</p></sec><sec id="s4-10"><title>Segmentation of OCT images</title><p>OCT B-scans of iridocorneal angle tissues were registered and segmented following established methods (<xref ref-type="bibr" rid="bib35">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib45">Meng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>) using SchlemmSeg software, which includes two modules: Schlemm I and Schlemm II. Briefly, OCT B-scans were automatically registered using our custom Schlemm I software for SC segmentation. The Schlemm II software package was then used to differentiate SC from scleral vessels, which were automatically marked. If SC was seen to be connected to collector channels (CC), manual separation of SC from CC was required, and was based on the shape of SC and speckling in the images generated by blood cells or other reflectors contained in blood vessels (<xref ref-type="bibr" rid="bib41">Mariampillai et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Huang et al., 2009</xref>; <xref ref-type="bibr" rid="bib17">Hendargo et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Li et al., 2014a</xref>; <xref ref-type="bibr" rid="bib54">Poole et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Meng et al., 2016</xref>). The speckle variance OCT-angiography images were generated based on the speckling in SC and vessels as described in detail in previous publication (<xref ref-type="bibr" rid="bib45">Meng et al., 2016</xref>). SC was easily differentiated from other vessels due to its size and location.</p></sec><sec id="s4-11"><title>Segmentation reproducibility</title><p>To test the reproducibility of the SC segmentation process, we evaluated both interobserver and intraobserver reproducibility. The segmentation of SC was independently performed by two individuals. The first observer (GL) conducted the experiments and made initial measurements, then repeated the measurements 1–2 months after the first examination to determine intraobserver reproducibility. The second observer (JC) was first given a training set of images to evaluate, then reviewed the images for the present study in a masked fashion to assess the interobserver reproducibility.</p></sec><sec id="s4-12"><title>iFEM determination of TM stiffness</title><p>In brief, the FEM technique allows one to compute the deformation of a structure due to loads/forces; here we computed the deformation of irideocorneal angle tissues (including the TM) due to changing IOP. In our iFEM approach, the stiffness of the TM was parametrically varied until computed SC deformations matched experimental observations, at which point we concluded that the TM stiffness specified in the FEM approach matched the actual (in vivo) value, while masked to treatment group. A pseudo-2D FEM geometry generated in our previous publication (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>) was used to calculate TM tissue stiffness based on OCT images. We have previously shown (<xref ref-type="bibr" rid="bib75">Wang et al., 2017a</xref>) that such a pseudo-3D approach does not yield results significantly different from a true 3D model, at a fraction of the workload. The model includes the TM, sclera/cornea, and the uvea, and is meshed with four-noded tetrahedral elements. Tissues are treated as incompressible, isotropic, and nonlinearly hyperelastic (incompressible Mooney-Rivlin material model). The TM is assigned a range of stiffnesses (20–240 kPa), and for each stiffness value, we simulate the deformation of irideocorneal angle tissues, thus determining the cross-sectional area of SC vs. IOP. The computed SC area is compared with experimental measurements, and the estimated TM stiffness is taken as the value that minimizes the least squares difference between the experimental and predicted normalized SC areas over the IOP range 10–20 mmHg. SC luminal pressure is estimated as previously described (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p></sec><sec id="s4-13"><title>AFM measurement of TM stiffness</title><p>TM stiffnesses were measured using a previously developed AFM technique on cryosections of mouse eyes (<xref ref-type="bibr" rid="bib76">Wang et al., 2017b</xref>; <xref ref-type="bibr" rid="bib77">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). Briefly, de-identified eyes coated with optimal cutting temperature compound (O.C.T.; Tissue-Tek) were cryo-sectioned from three different quadrants on a Microm Cryostar NX70 cryostat (Dreieich, Germany). For each quadrant, a few 10-µm-thick sagittal cryosections were collected on adhesive slides (Plus Gold Slide, Electron Microscopy Sciences, Hatfield, PA) and stored for up to 30 min in ice-cold PBS prior to AFM analysis.</p><p>Samples were then transferred to an MFP-3D-Bio AFM (Asylum Research, Santa Barbara, CA) and kept continuously immersed in PBS during measurements at room temperature (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). TM stiffnesses were measured following the same protocol we used previously (<xref ref-type="bibr" rid="bib76">Wang et al., 2017b</xref>). Specifically, cantilever probes were modified by attaching a spherical indenter of diameter 10 µm to smooth nanoscale variations in tissue mechanics. For each indentation, the indentation depth was 0.5–1 µm, with a maximum applied force of 7 nN and approach velocity of 8 µm/s. A Hertzian model was used to extract a Young’s modulus stiffness value from the force vs. indentation curves. For each cryosection, the TM was first localized as the region between the pigmented ciliary body and the inner wall endothelium of SC. Multiple locations in the TM region (typically 3–9) were probed by the cantilever and three repeated measurements were conducted at each location. The average from the three measurements was taken as the TM stiffness at that location. TM stiffnesses from all locations within a cryosection were then averaged to obtain the TM stiffness of that cryosection, and values for cryosections within a quadrant were averaged to obtain the TM stiffness in that quadrant. The mean stiffness of all quadrants was taken as the TM stiffness of the eye. Typically, there were 135 force curves acquired per eye (three force curves per location, typically five locations per cryosection, and typically nine cryosections per eye). A small number of measured TM stiffness values were excluded in a post hoc analysis if there was disagreement from a second reviewer as to whether the measurement location lay within the TM.</p></sec><sec id="s4-14"><title>Histology, immunohistochemistry, and TEM</title><p>After OCT imaging, mice were decapitated under anesthesia, and eyes were collected and immersion fixed in 4% paraformaldehyde at 4°C overnight. The eyes were then bisected, and the posterior segments and lenses were removed. The anterior segments were cut into four quadrants. For immunostaining, each quadrant was embedded into LR-White resin, and 1 µm sections were cut and immunostained with antibodies that specifically recognized either αSMA (1:100 dilution, rabbit polyclonal, ab5694, Abcam, Cambridge, MA) or FN (1:50 dilution, mouse monoclonal, Santa Cruz, Dallas, TX). The secondary antibodies were peroxidase-conjugated AnffiniPure Goat Anti-Rabbit or mouse IgG H and L (Alexa Fluor 488; Jackson ImmunoResearch Laboratories, West Grove, PA) at 1:500 dilution. All sections were processed at the same time. Images were captured using a Nikon Eclipse 90i confocal laser scanning microscope (Melville, NY). Images from NT- and PL-treated eyes were collected at identical intensity and gain settings on the same day (z stacks of nine 0.5 μm optical sections for each image) (<xref ref-type="bibr" rid="bib36">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). For electron microscopy studies, one quadrant per eye of the anterior segment was fixed in 2% glutaraldehyde and embedded in Epon resin and 65 nm sagittal thin sections were cut through iridocorneal tissues using an ultramicrotome (LEICA EM UC6, Leica Mikrosysteme GmbH, A-1170, Wien, Austria). Sections were stained with uranyl acetate/lead citrate and examined with a JEM-1400 electron microscope (JEOL USA, Peabody, MA).</p></sec><sec id="s4-15"><title>Quantitative analysis of FN and α-SMA</title><p>Using ImageJ software, the TM from each image was manually segmented (region of interest, ROI) in a masked fashion by one co-author (MK), and fluorescence intensity (mean grayscale value) within each ROI was determined (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for example). The inner wall of SC provided the outer boundary of the ROI, while pigment from ciliary body structures served as the interior boundary. Only the filtering region of the TM (i.e., the region below SC) was analyzed.</p></sec><sec id="s4-16"><title>Quantification of ECM content in JCT</title><p>To quantify ECM in the JCT under the inner wall of SC, images were captured at 8000× magnification and masked as to the identity of the treatment group. Images were quantified in two ways. First, they were scored using a pre-established semi-quantitative scoring system by two individuals (WDS and CRE) with extensive experience in viewing TEM images of the conventional outflow pathway. Specifically, the density and extent of the ECM in the JCT region, in particular below the inner wall of SC, was scored on a scale of 0–2, with 0 representing ‘normal’ appearing basal lamina, 2 representing continuous basement membrane materials (BMM) such as observed in the mouse steroid OHT model (<xref ref-type="bibr" rid="bib52">Overby et al., 2014</xref>), and 1 representing conditions between the two extremes. Thus, images were included whereby the inner wall of SC was clearly visible, and images were of sufficient quality to examine its basal lamina.</p><p>The second quantification method followed an existing approach (<xref ref-type="bibr" rid="bib52">Overby et al., 2014</xref>) wherein coverage of BMM immediately underlying the inner wall of SC was measured. In brief, the lengths of the continuous BMM in contact with the inner wall of SC and the total length of the inner wall were measured using ImageJ software as described previously in 97 TEM images from 50 mice (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> for an example). Then, the sum of the continuous BMM length was divided by the total inner wall length to compute a ratio representing the percentage of the inner wall underlain by BMM. Only continuous BMM in contact with the inner wall was included in the BMM measurements, that is, regions where continuous BMM showed an optically clear offset from the inner wall were excluded. Ratio values from multiple images from the same eyes were averaged.</p></sec><sec id="s4-17"><title>Statistical analyses</title><p>Due to the fact that IOPs are normally distributed and the expected directional (lowering only) effect of NT on IOP, we analyzed patient IOP data using a paired t-test with one tail, assuming equal variance. To analyze IOP measurements in mice, the time points from 3 to 28 days in the prevention study, or the time points from 1 to 4 days post-NT/PL delivery in the reversal study, were averaged from each eye to produce a single average IOP value per eye for subsequent data analysis. The Mann-Whitney U-test was used for analyzing significant difference between groups for IOP and OCT images. To analyze outflow facility measurements, we used the well-established fact that the underlying distribution of outflow facility in mice is log-normally distributed (<xref ref-type="bibr" rid="bib65">Sherwood et al., 2016</xref>). Thus, a weighted paired or unpaired (two-way) t-test (<xref ref-type="bibr" rid="bib65">Sherwood et al., 2016</xref>) was applied to the log-transformed facilities. To analyze data quantifying fluorescence intensity, an F-test of difference among means from ANOVA was used, with a GEE (generalized estimating equations) approach applied to account for multiple observations per mouse. To analyze BMM in mice, we used two different methods: a parametric approach and a non-parametric approach. In the parametric approach, an F-test of difference among means was used as part of an ANOVA, followed by pair-wise comparisons based on t-tests of differences between means. In the non-parametric analysis, a Kruskal-Wallis ANOVA was used to test for difference among medians, followed by pair-wise comparisons based on Wilcoxon rank sum tests for differences between medians. Data in box and whisker plots show median, 25th percentile, and 75th percentile (boxes), as well as minimum and maximum values (whiskers). Data in other plot formats are presented in the form of mean and 95% confidence interval or mean and standard error of the mean (SEM), as noted. A value of p≤0.05 was considered statistically significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Ying Hao (Duke Eye Center Core Facility), who prepared histology sections and helped with TEM. Dr. Vibhuti Agrahari helped with the preparation and characterization of the NPs. Dr. Sandra Stinnett performed statistical analysis of data quantifying basement membrane deposits and stiffness measurements. We acknowledge funding support from the BrightFocus Foundation, Clarksburg, MA; Research to Prevent Blindness Foundation, New York; the Georgia Research Alliance, Atlanta, GA; Aerie Pharmaceuticals, Durham, NC; and National Institutes of Health, Washington, DC (EY031710, EY030124, and EY005722). Aerie Pharmaceuticals had input into the choice of several standard endpoint measurements (IOP, outflow facility, smooth muscle actin, and FN expression), but did not have input into other measures, such as TEM (including quantification), OCT imaging and finite element modeling, AFM, and quantification of immunolabeling results. Aerie Pharmaceuticals had no role in the conduct of the research, and other sponsors and funding organizations had no role in either the design or conduct of the research.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Dr. Kopczynski is an employee of Aerie Pharmaceuticals</p></fn><fn fn-type="COI-statement" id="conf3"><p>Dr. Samples has participated in speaker's bureaus for Allergan, Aerie, Bausch and Lomb, Novartis, Santen, Akorn, Nicox and Roche.</p></fn><fn fn-type="COI-statement" id="conf4"><p>Dr. Challa currently owns equity in Aerie Pharmaceuticals.</p></fn><fn fn-type="COI-statement" id="conf5"><p>Dr. Ethier has received consulting fees from Equinox and EyeD Pharma.</p></fn><fn fn-type="COI-statement" id="conf6"><p>Dr. Stamer has received research support from Aerie Pharmaceuticals, Aerpio, Broadwing Bio, Editas Medicine, Bausch, Allergan and Regeneron; currently serves on scientific advisory boards for Qlaris, Aerpio, Glauconix and Broadwing Bio, and has stock options in Glauconix and Qlaris.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Validation, Visualization</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation, Validation, Investigation</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Writing - original draft</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Software, Funding acquisition</p></fn><fn fn-type="con" id="con14"><p>Data curation, Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con15"><p>Data curation, Formal analysis, Supervision, Validation, Investigation</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: Of two cohorts of de-identified patients, the first was drawn from patients seen at the Duke Eye Center, using IRB-approved access to patient data via the EPIC electronic medical record system using SlicerDicer software. The second cohort was derived from comprehensive retrospective chart review of patients at two different clinic sites: The Eye Clinic in Portland, Oregon and Olympia Eye Clinic in Olympia, Washington.</p></fn><fn fn-type="other" id="fn2"><p>Animal experimentation: The mice were handled in accordance with approved protocols (A020-16-02 and A001-19-01, Institutional Animal Care and Use Committee of Duke University) and in compliance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Estimated pressures within Schlemm’s canal (SC) lumen as a function of clamped intraocular pressure (IOP) levels using two-series resistor model of conventional outflow pathway described previously.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-60831-supp1-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-60831-transrepform-v1.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1, 2, 3, 4 and 5.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>A-Hassan</surname> <given-names>E</given-names></name><name><surname>Heinz</surname> <given-names>WF</given-names></name><name><surname>Antonik</surname> <given-names>MD</given-names></name><name><surname>D'Costa</surname> <given-names>NP</given-names></name><name><surname>Nageswaran</surname> <given-names>S</given-names></name><name><surname>Schoenenberger</surname> <given-names>CA</given-names></name><name><surname>Hoh</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Relative microelastic mapping of living cells by atomic force microscopy</article-title><source>Biophysical Journal</source><volume>74</volume><fpage>1564</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(98)77868-3</pub-id><pub-id pub-id-type="pmid">9512052</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrahari</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Agrahari</surname> <given-names>V</given-names></name><name><surname>Navarro</surname> <given-names>I</given-names></name><name><surname>Perkumas</surname> <given-names>K</given-names></name><name><surname>Mandal</surname> <given-names>A</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name><name><surname>Mitra</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells</article-title><source>Nanomedicine</source><volume>12</volume><fpage>1911</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.2217/nnm-2017-0140</pub-id><pub-id pub-id-type="pmid">28756742</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahler</surname> <given-names>CK</given-names></name><name><surname>Howell</surname> <given-names>KG</given-names></name><name><surname>Hann</surname> <given-names>CR</given-names></name><name><surname>Fautsch</surname> <given-names>MP</given-names></name><name><surname>Johnson</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments</article-title><source>American Journal of Ophthalmology</source><volume>145</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2007.09.001</pub-id><pub-id pub-id-type="pmid">17988642</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>Intraocular Pressure Response to Topical Corticosteroids</article-title><source>Investigative Ophthalmology</source><volume>4</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">14283013</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boussommier-Calleja</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Wilson</surname> <given-names>A</given-names></name><name><surname>Ziskind</surname> <given-names>T</given-names></name><name><surname>Scinteie</surname> <given-names>OE</given-names></name><name><surname>Ashpole</surname> <given-names>NE</given-names></name><name><surname>Sherwood</surname> <given-names>JM</given-names></name><name><surname>Farsiu</surname> <given-names>S</given-names></name><name><surname>Challa</surname> <given-names>P</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name><name><surname>Downs</surname> <given-names>JC</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name><name><surname>Overby</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Physical factors affecting outflow facility measurements in mice</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>8331</fpage><lpage>8339</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-17106</pub-id><pub-id pub-id-type="pmid">26720486</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunger</surname> <given-names>BM</given-names></name><name><surname>Fuchshofer</surname> <given-names>R</given-names></name><name><surname>Tamm</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The aqueous humor outflow pathways in Glaucoma: a unifying concept of disease mechanisms and causative treatment</article-title><source>European Journal of Pharmaceutics and Biopharmaceutics</source><volume>95</volume><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.04.029</pub-id><pub-id pub-id-type="pmid">25957840</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brubaker</surname> <given-names>RF</given-names></name><name><surname>Schoff</surname> <given-names>EO</given-names></name><name><surname>Nau</surname> <given-names>CB</given-names></name><name><surname>Carpenter</surname> <given-names>SP</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Vandenburgh</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics</article-title><source>American Journal of Ophthalmology</source><volume>131</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(00)00843-6</pub-id><pub-id pub-id-type="pmid">11162974</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brubaker</surname> <given-names>RF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Goldmann's equation and clinical measures of aqueous dynamics</article-title><source>Experimental Eye Research</source><volume>78</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2003.07.002</pub-id><pub-id pub-id-type="pmid">15106943</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucolo</surname> <given-names>C</given-names></name><name><surname>Platania</surname> <given-names>CB</given-names></name><name><surname>Reibaldi</surname> <given-names>M</given-names></name><name><surname>Bonfiglio</surname> <given-names>V</given-names></name><name><surname>Longo</surname> <given-names>A</given-names></name><name><surname>Salomone</surname> <given-names>S</given-names></name><name><surname>Drago</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Controversies in Glaucoma: current medical treatment and drug development</article-title><source>Current Pharmaceutical Design</source><volume>21</volume><fpage>4673</fpage><lpage>4681</lpage><pub-id pub-id-type="doi">10.2174/1381612821666150909095553</pub-id><pub-id pub-id-type="pmid">26350532</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>AF</given-names></name><name><surname>Steely</surname> <given-names>HT</given-names></name><name><surname>Dickerson</surname> <given-names>JE</given-names></name><name><surname>English-Wright</surname> <given-names>S</given-names></name><name><surname>Stropki</surname> <given-names>K</given-names></name><name><surname>McCartney</surname> <given-names>MD</given-names></name><name><surname>Jacobson</surname> <given-names>N</given-names></name><name><surname>Shepard</surname> <given-names>AR</given-names></name><name><surname>Clark</surname> <given-names>JI</given-names></name><name><surname>Matsushima</surname> <given-names>H</given-names></name><name><surname>Peskind</surname> <given-names>ER</given-names></name><name><surname>Leverenz</surname> <given-names>JB</given-names></name><name><surname>Wilkinson</surname> <given-names>CW</given-names></name><name><surname>Swiderski</surname> <given-names>RE</given-names></name><name><surname>Fingert</surname> <given-names>JH</given-names></name><name><surname>Sheffield</surname> <given-names>VC</given-names></name><name><surname>Stone</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Glucocorticoid induction of the Glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>42</volume><fpage>1769</fpage><lpage>1780</lpage><pub-id pub-id-type="pmid">11431441</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crespi</surname> <given-names>M</given-names></name><name><surname>Dulbecco</surname> <given-names>P</given-names></name><name><surname>De Ceglie</surname> <given-names>A</given-names></name><name><surname>Conio</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Strictures in Crohn's Disease: From Pathophysiology to Treatment</article-title><source>Digestive Diseases and Sciences</source><volume>65</volume><fpage>1904</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1007/s10620-020-06227-0</pub-id><pub-id pub-id-type="pmid">32279173</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ethier</surname> <given-names>CR</given-names></name><name><surname>Simmons</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2007">2007</year><source>Introductory Biomechanics: From Cells to Organisms</source><publisher-loc>New York</publisher-loc><publisher-name>Cambridge University Press</publisher-name></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnock-Jones</surname> <given-names>KP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ripasudil: first global approval</article-title><source>Drugs</source><volume>74</volume><fpage>2211</fpage><lpage>2215</lpage><pub-id pub-id-type="doi">10.1007/s40265-014-0333-2</pub-id><pub-id pub-id-type="pmid">25414122</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparics</surname> <given-names>Á</given-names></name><name><surname>Sebe</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MRTFs- master regulators of EMT</article-title><source>Developmental Dynamics</source><volume>247</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1002/dvdy.24544</pub-id><pub-id pub-id-type="pmid">28681541</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeck</surname> <given-names>IM</given-names></name><name><surname>Rouwen</surname> <given-names>TJ</given-names></name><name><surname>Timmer-de Mik</surname> <given-names>L</given-names></name><name><surname>de Bruin-Weller</surname> <given-names>MS</given-names></name><name><surname>Bruijnzeel-Koomen</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Topical corticosteroids in atopic dermatitis and the risk of Glaucoma and cataracts</article-title><source>Journal of the American Academy of Dermatology</source><volume>64</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.01.035</pub-id><pub-id pub-id-type="pmid">21122943</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haudek</surname> <given-names>SB</given-names></name><name><surname>Gupta</surname> <given-names>D</given-names></name><name><surname>Dewald</surname> <given-names>O</given-names></name><name><surname>Schwartz</surname> <given-names>RJ</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Trial</surname> <given-names>J</given-names></name><name><surname>Entman</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation</article-title><source>Cardiovascular Research</source><volume>83</volume><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp135</pub-id><pub-id pub-id-type="pmid">19406912</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendargo</surname> <given-names>HC</given-names></name><name><surname>Estrada</surname> <given-names>R</given-names></name><name><surname>Chiu</surname> <given-names>SJ</given-names></name><name><surname>Tomasi</surname> <given-names>C</given-names></name><name><surname>Farsiu</surname> <given-names>S</given-names></name><name><surname>Izatt</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Automated non-rigid registration and mosaicing for robust imaging of distinct retinal capillary beds using speckle variance optical coherence tomography</article-title><source>Biomedical Optics Express</source><volume>4</volume><fpage>803</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1364/BOE.4.000803</pub-id><pub-id pub-id-type="pmid">23761845</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname> <given-names>H</given-names></name><name><surname>Roberts</surname> <given-names>AL</given-names></name><name><surname>McDowell</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nuclear factor-kappa beta signaling is required for transforming growth factor Beta-2 induced ocular hypertension</article-title><source>Experimental Eye Research</source><volume>191</volume><elocation-id>107920</elocation-id><pub-id pub-id-type="doi">10.1016/j.exer.2020.107920</pub-id><pub-id pub-id-type="pmid">31923415</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holvoet</surname> <given-names>T</given-names></name><name><surname>Devriese</surname> <given-names>S</given-names></name><name><surname>Castermans</surname> <given-names>K</given-names></name><name><surname>Boland</surname> <given-names>S</given-names></name><name><surname>Leysen</surname> <given-names>D</given-names></name><name><surname>Vandewynckel</surname> <given-names>YP</given-names></name><name><surname>Devisscher</surname> <given-names>L</given-names></name><name><surname>Van den Bossche</surname> <given-names>L</given-names></name><name><surname>Van Welden</surname> <given-names>S</given-names></name><name><surname>Dullaers</surname> <given-names>M</given-names></name><name><surname>Vandenbroucke</surname> <given-names>RE</given-names></name><name><surname>De Rycke</surname> <given-names>R</given-names></name><name><surname>Geboes</surname> <given-names>K</given-names></name><name><surname>Bourin</surname> <given-names>A</given-names></name><name><surname>Defert</surname> <given-names>O</given-names></name><name><surname>Hindryckx</surname> <given-names>P</given-names></name><name><surname>De Vos</surname> <given-names>M</given-names></name><name><surname>Laukens</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Treatment of intestinal fibrosis in experimental inflammatory bowel disease by the pleiotropic actions of a local rho kinase inhibitor</article-title><source>Gastroenterology</source><volume>153</volume><fpage>1054</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.06.013</pub-id><pub-id pub-id-type="pmid">28642198</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Q</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A new adaptive interpolation algorithm for 3D ultrasound imaging with speckle reduction and edge preservation</article-title><source>Computerized Medical Imaging and Graphics</source><volume>33</volume><fpage>100</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.compmedimag.2008.10.006</pub-id><pub-id pub-id-type="pmid">19117725</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue-Mochita</surname> <given-names>M</given-names></name><name><surname>Inoue</surname> <given-names>T</given-names></name><name><surname>Fujimoto</surname> <given-names>T</given-names></name><name><surname>Kameda</surname> <given-names>T</given-names></name><name><surname>Awai-Kasaoka</surname> <given-names>N</given-names></name><name><surname>Ohtsu</surname> <given-names>N</given-names></name><name><surname>Kimoto</surname> <given-names>K</given-names></name><name><surname>Tanihara</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>p38 MAP kinase inhibitor suppresses transforming growth factor-β2-induced type 1 collagen production in trabecular meshwork cells</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0120774</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0120774</pub-id><pub-id pub-id-type="pmid">25799097</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isobe</surname> <given-names>T</given-names></name><name><surname>Mizuno</surname> <given-names>K</given-names></name><name><surname>Kaneko</surname> <given-names>Y</given-names></name><name><surname>Ohta</surname> <given-names>M</given-names></name><name><surname>Koide</surname> <given-names>T</given-names></name><name><surname>Tanabe</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits</article-title><source>Current Eye Research</source><volume>39</volume><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.3109/02713683.2013.874444</pub-id><pub-id pub-id-type="pmid">24502505</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>DH</given-names></name><name><surname>Bradley</surname> <given-names>JM</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>31</volume><fpage>2568</fpage><lpage>2571</lpage><pub-id pub-id-type="pmid">2125032</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Gottanka</surname> <given-names>J</given-names></name><name><surname>Flügel</surname> <given-names>C</given-names></name><name><surname>Hoffmann</surname> <given-names>F</given-names></name><name><surname>Futa</surname> <given-names>R</given-names></name><name><surname>Lütjen-Drecoll</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids</article-title><source>Archives of Ophthalmology</source><volume>115</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1001/archopht.1997.01100150377011</pub-id><pub-id pub-id-type="pmid">9076211</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>DH</given-names></name><name><surname>Knepper</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Microscale analysis of the glycosaminoglycans of human trabecular meshwork: a study in perfusion cultured eyes</article-title><source>Journal of Glaucoma</source><volume>3</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">19920553</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junglas</surname> <given-names>B</given-names></name><name><surname>Kuespert</surname> <given-names>S</given-names></name><name><surname>Seleem</surname> <given-names>AA</given-names></name><name><surname>Struller</surname> <given-names>T</given-names></name><name><surname>Ullmann</surname> <given-names>S</given-names></name><name><surname>Bösl</surname> <given-names>M</given-names></name><name><surname>Bosserhoff</surname> <given-names>A</given-names></name><name><surname>Köstler</surname> <given-names>J</given-names></name><name><surname>Wagner</surname> <given-names>R</given-names></name><name><surname>Tamm</surname> <given-names>ER</given-names></name><name><surname>Fuchshofer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Connective tissue growth factor causes Glaucoma by modifying the actin cytoskeleton of the trabecular meshwork</article-title><source>The American Journal of Pathology</source><volume>180</volume><fpage>2386</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.02.030</pub-id><pub-id pub-id-type="pmid">22542845</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazemi</surname> <given-names>A</given-names></name><name><surname>McLaren</surname> <given-names>JW</given-names></name><name><surname>Kopczynski</surname> <given-names>CC</given-names></name><name><surname>Heah</surname> <given-names>TG</given-names></name><name><surname>Novack</surname> <given-names>GD</given-names></name><name><surname>Sit</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>34</volume><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1089/jop.2017.0138</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname> <given-names>KE</given-names></name><name><surname>Aga</surname> <given-names>M</given-names></name><name><surname>Bradley</surname> <given-names>JM</given-names></name><name><surname>Kelley</surname> <given-names>MJ</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Extracellular matrix turnover and outflow resistance</article-title><source>Experimental Eye Research</source><volume>88</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2008.11.023</pub-id><pub-id pub-id-type="pmid">19087875</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knipe</surname> <given-names>RS</given-names></name><name><surname>Tager</surname> <given-names>AM</given-names></name><name><surname>Liao</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis</article-title><source>Pharmacological Reviews</source><volume>67</volume><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1124/pr.114.009381</pub-id><pub-id pub-id-type="pmid">25395505</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopczynski</surname> <given-names>CC</given-names></name><name><surname>Heah</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle Glaucoma or ocular hypertension</article-title><source>Drugs Today</source><volume>54</volume><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1358/dot.2018.54.8.2849627</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korol</surname> <given-names>A</given-names></name><name><surname>Taiyab</surname> <given-names>A</given-names></name><name><surname>West-Mays</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RhoA/ROCK signaling regulates TGFβ-induced epithelial-mesenchymal transition of Lens epithelial cells through MRTF-A</article-title><source>Molecular Medicine</source><volume>22</volume><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.2119/molmed.2016.00041</pub-id><pub-id pub-id-type="pmid">27704140</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Last</surname> <given-names>JA</given-names></name><name><surname>Pan</surname> <given-names>T</given-names></name><name><surname>Ding</surname> <given-names>Y</given-names></name><name><surname>Reilly</surname> <given-names>CM</given-names></name><name><surname>Keller</surname> <given-names>K</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name><name><surname>Fautsch</surname> <given-names>MP</given-names></name><name><surname>Murphy</surname> <given-names>CJ</given-names></name><name><surname>Russell</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Elastic Modulus determination of normal and glaucomatous human trabecular meshwork</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>52</volume><fpage>2147</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-6342</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Farsiu</surname> <given-names>S</given-names></name><name><surname>Chiu</surname> <given-names>SJ</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name><name><surname>Lütjen-Drecoll</surname> <given-names>E</given-names></name><name><surname>Overby</surname> <given-names>DR</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>Pilocarpine-Induced dilation of schlemm's Canal and Prevention of Lumen Collapse at Elevated Intraocular Pressures in Living Mice Visualized by OCT</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>55</volume><fpage>3737</fpage><lpage>3746</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-13700</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Farsiu</surname> <given-names>S</given-names></name><name><surname>Qiu</surname> <given-names>J</given-names></name><name><surname>Dixon</surname> <given-names>A</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>McKinnon</surname> <given-names>SJ</given-names></name><name><surname>Yuan</surname> <given-names>F</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography</article-title><source>Molecular Vision</source><volume>20</volume><fpage>1695</fpage><lpage>1709</lpage><pub-id pub-id-type="pmid">25558173</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Mukherjee</surname> <given-names>D</given-names></name><name><surname>Navarro</surname> <given-names>I</given-names></name><name><surname>Ashpole</surname> <given-names>NE</given-names></name><name><surname>Sherwood</surname> <given-names>JM</given-names></name><name><surname>Chang</surname> <given-names>J</given-names></name><name><surname>Overby</surname> <given-names>DR</given-names></name><name><surname>Yuan</surname> <given-names>F</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name><name><surname>Kopczynski</surname> <given-names>CC</given-names></name><name><surname>Farsiu</surname> <given-names>S</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes</article-title><source>European Journal of Pharmacology</source><volume>787</volume><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2016.04.002</pub-id><pub-id pub-id-type="pmid">27085895</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Torrejon</surname> <given-names>KY</given-names></name><name><surname>Unser</surname> <given-names>AM</given-names></name><name><surname>Ahmed</surname> <given-names>F</given-names></name><name><surname>Navarro</surname> <given-names>ID</given-names></name><name><surname>Baumgartner</surname> <given-names>RA</given-names></name><name><surname>Albers</surname> <given-names>DS</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Trabodenoson, an Adenosine mimetic with A1 receptor selectivity lowers intraocular pressure by increasing conventional outflow facility in mice</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>59</volume><fpage>383</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1167/iovs.17-23212</pub-id><pub-id pub-id-type="pmid">29346804</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name><name><surname>Agrahari</surname> <given-names>V</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Navarro</surname> <given-names>I</given-names></name><name><surname>Sherwood</surname> <given-names>JM</given-names></name><name><surname>Crews</surname> <given-names>K</given-names></name><name><surname>Farsiu</surname> <given-names>S</given-names></name><name><surname>Gonzalez</surname> <given-names>P</given-names></name><name><surname>Lin</surname> <given-names>CW</given-names></name><name><surname>Mitra</surname> <given-names>AK</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>In vivo measurement of trabecular meshwork stiffness in a corticosteroid-induced ocular hypertensive mouse model</article-title><source>PNAS</source><volume>116</volume><fpage>1714</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1073/pnas.1814889116</pub-id><pub-id pub-id-type="pmid">30651311</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>CW</given-names></name><name><surname>Sherman</surname> <given-names>B</given-names></name><name><surname>Moore</surname> <given-names>LA</given-names></name><name><surname>Laethem</surname> <given-names>CL</given-names></name><name><surname>Lu</surname> <given-names>DW</given-names></name><name><surname>Pattabiraman</surname> <given-names>PP</given-names></name><name><surname>Rao</surname> <given-names>PV</given-names></name><name><surname>deLong</surname> <given-names>MA</given-names></name><name><surname>Kopczynski</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of Glaucoma</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>34</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1089/jop.2017.0023</pub-id><pub-id pub-id-type="pmid">28609185</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>McNally</surname> <given-names>S</given-names></name><name><surname>Kilpatrick</surname> <given-names>JI</given-names></name><name><surname>Jarvis</surname> <given-names>SP</given-names></name><name><surname>O'Brien</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aging and ocular tissue stiffness in Glaucoma</article-title><source>Survey of Ophthalmology</source><volume>63</volume><fpage>56</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2017.06.007</pub-id><pub-id pub-id-type="pmid">28666629</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lütjen-Drecoll</surname> <given-names>E</given-names></name><name><surname>Shimizu</surname> <given-names>T</given-names></name><name><surname>Rohrbach</surname> <given-names>M</given-names></name><name><surname>Rohen</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes</article-title><source>Experimental Eye Research</source><volume>42</volume><fpage>443</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/0014-4835(86)90004-7</pub-id><pub-id pub-id-type="pmid">3720863</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariampillai</surname> <given-names>A</given-names></name><name><surname>Standish</surname> <given-names>BA</given-names></name><name><surname>Moriyama</surname> <given-names>EH</given-names></name><name><surname>Khurana</surname> <given-names>M</given-names></name><name><surname>Munce</surname> <given-names>NR</given-names></name><name><surname>Leung</surname> <given-names>MK</given-names></name><name><surname>Jiang</surname> <given-names>J</given-names></name><name><surname>Cable</surname> <given-names>A</given-names></name><name><surname>Wilson</surname> <given-names>BC</given-names></name><name><surname>Vitkin</surname> <given-names>IA</given-names></name><name><surname>Yang</surname> <given-names>VX</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Speckle variance detection of microvasculature using swept-source optical coherence tomography</article-title><source>Optics Letters</source><volume>33</volume><fpage>1530</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1364/OL.33.001530</pub-id><pub-id pub-id-type="pmid">18594688</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinković</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Tschumperlin</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>48</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2012-0335OC</pub-id><pub-id pub-id-type="pmid">23258227</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matzke</surname> <given-names>R</given-names></name><name><surname>Jacobson</surname> <given-names>K</given-names></name><name><surname>Radmacher</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Direct, high-resolution measurement of furrow stiffening during division of adherent cells</article-title><source>Nature Cell Biology</source><volume>3</volume><fpage>607</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1038/35078583</pub-id><pub-id pub-id-type="pmid">11389447</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMurtry</surname> <given-names>IF</given-names></name><name><surname>Abe</surname> <given-names>K</given-names></name><name><surname>Ota</surname> <given-names>H</given-names></name><name><surname>Fagan</surname> <given-names>KA</given-names></name><name><surname>Oka</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rho kinase-mediated vasoconstriction in pulmonary hypertension</article-title><source>Advances in Experimental Medicine and Biology</source><volume>661</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-500-2_19</pub-id><pub-id pub-id-type="pmid">20204738</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname> <given-names>XM</given-names></name><name><surname>Nikolic-Paterson</surname> <given-names>DJ</given-names></name><name><surname>Lan</surname> <given-names>HY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TGF-β: the master regulator of fibrosis</article-title><source>Nature Reviews Nephrology</source><volume>12</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2016.48</pub-id><pub-id pub-id-type="pmid">27108839</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montecchi-Palmer</surname> <given-names>M</given-names></name><name><surname>Bermudez</surname> <given-names>JY</given-names></name><name><surname>Webber</surname> <given-names>HC</given-names></name><name><surname>Patel</surname> <given-names>GC</given-names></name><name><surname>Clark</surname> <given-names>AF</given-names></name><name><surname>Mao</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tgfβ2 induces the formation of Cross-Linked actin networks (CLANs) in human trabecular meshwork cells through the smad and Non-Smad dependent pathways</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>58</volume><fpage>1288</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-19672</pub-id><pub-id pub-id-type="pmid">28241317</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroi</surname> <given-names>SE</given-names></name><name><surname>Gottfredsdottir</surname> <given-names>MS</given-names></name><name><surname>Schteingart</surname> <given-names>MT</given-names></name><name><surname>Elner</surname> <given-names>SG</given-names></name><name><surname>Lee</surname> <given-names>CM</given-names></name><name><surname>Schertzer</surname> <given-names>RM</given-names></name><name><surname>Abrams</surname> <given-names>GW</given-names></name><name><surname>Johnson</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cystoid macular edema associated with latanoprost therapy in a case series of patients with Glaucoma and ocular hypertension</article-title><source>Ophthalmology</source><volume>106</volume><fpage>1024</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(99)00528-X</pub-id><pub-id pub-id-type="pmid">10328408</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname> <given-names>G</given-names></name><name><surname>De Michieli</surname> <given-names>F</given-names></name><name><surname>Bongiovanni</surname> <given-names>D</given-names></name><name><surname>Parente</surname> <given-names>R</given-names></name><name><surname>Framarin</surname> <given-names>L</given-names></name><name><surname>Leone</surname> <given-names>N</given-names></name><name><surname>Berrutti</surname> <given-names>M</given-names></name><name><surname>Gambino</surname> <given-names>R</given-names></name><name><surname>Cassader</surname> <given-names>M</given-names></name><name><surname>Cohney</surname> <given-names>S</given-names></name><name><surname>Paschetta</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>New pharmacologic agents that target inflammation and fibrosis in nonalcoholic Steatohepatitis-Related kidney disease</article-title><source>Clinical Gastroenterology and Hepatology</source><volume>15</volume><fpage>972</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2016.08.002</pub-id><pub-id pub-id-type="pmid">27521506</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname> <given-names>E</given-names></name><name><surname>Nakajima</surname> <given-names>T</given-names></name><name><surname>Minagawa</surname> <given-names>Y</given-names></name><name><surname>Shearer</surname> <given-names>TR</given-names></name><name><surname>Azuma</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes</article-title><source>Journal of Pharmaceutical Sciences</source><volume>94</volume><fpage>701</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1002/jps.20285</pub-id><pub-id pub-id-type="pmid">15682386</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname> <given-names>S</given-names></name><name><surname>Goa</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Loteprednol etabonate: clinical potential in the management of ocular inflammation</article-title><source>BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</source><volume>10</volume><fpage>329</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.2165/00063030-199810040-00007</pub-id><pub-id pub-id-type="pmid">18020605</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Applications for ROCK kinase inhibition</article-title><source>Current Opinion in Cell Biology</source><volume>20</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2008.01.002</pub-id><pub-id pub-id-type="pmid">18282695</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overby</surname> <given-names>DR</given-names></name><name><surname>Bertrand</surname> <given-names>J</given-names></name><name><surname>Tektas</surname> <given-names>OY</given-names></name><name><surname>Boussommier-Calleja</surname> <given-names>A</given-names></name><name><surname>Schicht</surname> <given-names>M</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name><name><surname>Woodward</surname> <given-names>DF</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name><name><surname>Lütjen-Drecoll</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>55</volume><fpage>4922</fpage><lpage>4933</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-14429</pub-id><pub-id pub-id-type="pmid">25028360</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattabiraman</surname> <given-names>PP</given-names></name><name><surname>Rao</surname> <given-names>PV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mechanistic basis of rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells</article-title><source>American Journal of Physiology-Cell Physiology</source><volume>298</volume><fpage>C749</fpage><lpage>C763</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00317.2009</pub-id><pub-id pub-id-type="pmid">19940066</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poole</surname> <given-names>KM</given-names></name><name><surname>McCormack</surname> <given-names>DR</given-names></name><name><surname>Patil</surname> <given-names>CA</given-names></name><name><surname>Duvall</surname> <given-names>CL</given-names></name><name><surname>Skala</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantifying the vascular response to ischemia with speckle variance optical coherence tomography</article-title><source>Biomedical Optics Express</source><volume>5</volume><fpage>4118</fpage><lpage>4130</lpage><pub-id pub-id-type="doi">10.1364/BOE.5.004118</pub-id><pub-id pub-id-type="pmid">25574425</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghunathan</surname> <given-names>VK</given-names></name><name><surname>Morgan</surname> <given-names>JT</given-names></name><name><surname>Dreier</surname> <given-names>B</given-names></name><name><surname>Reilly</surname> <given-names>CM</given-names></name><name><surname>Thomasy</surname> <given-names>SM</given-names></name><name><surname>Wood</surname> <given-names>JA</given-names></name><name><surname>Ly</surname> <given-names>I</given-names></name><name><surname>Tuyen</surname> <given-names>BC</given-names></name><name><surname>Hughbanks</surname> <given-names>M</given-names></name><name><surname>Murphy</surname> <given-names>CJ</given-names></name><name><surname>Russell</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of substratum stiffness in modulating genes associated with extracellular matrix and mechanotransducers YAP and TAZ</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>54</volume><fpage>378</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-11007</pub-id><pub-id pub-id-type="pmid">23258147</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghunathan</surname> <given-names>VK</given-names></name><name><surname>Morgan</surname> <given-names>JT</given-names></name><name><surname>Park</surname> <given-names>SA</given-names></name><name><surname>Weber</surname> <given-names>D</given-names></name><name><surname>Phinney</surname> <given-names>BS</given-names></name><name><surname>Murphy</surname> <given-names>CJ</given-names></name><name><surname>Russell</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dexamethasone stiffens trabecular meshwork, trabecular meshwork cells, and matrix</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>4447</fpage><lpage>4459</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-16739</pub-id><pub-id pub-id-type="pmid">26193921</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname> <given-names>PV</given-names></name><name><surname>Deng</surname> <given-names>PF</given-names></name><name><surname>Kumar</surname> <given-names>J</given-names></name><name><surname>Epstein</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>42</volume><fpage>1029</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">11274082</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname> <given-names>R</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Le</surname> <given-names>TD</given-names></name><name><surname>Kopczynski</surname> <given-names>C</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name><name><surname>Gong</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Netarsudil increases outflow facility in human eyes through multiple mechanisms</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>57</volume><fpage>6197</fpage><lpage>6209</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-20189</pub-id><pub-id pub-id-type="pmid">27842161</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rönkkö</surname> <given-names>S</given-names></name><name><surname>Rekonen</surname> <given-names>P</given-names></name><name><surname>Kaarniranta</surname> <given-names>K</given-names></name><name><surname>Puustjärvi</surname> <given-names>T</given-names></name><name><surname>Teräsvirta</surname> <given-names>M</given-names></name><name><surname>Uusitalo</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle Glaucoma and exfoliation Glaucoma</article-title><source>Graefe's Archive for Clinical and Experimental Ophthalmology</source><volume>245</volume><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1007/s00417-006-0440-1</pub-id><pub-id pub-id-type="pmid">17028863</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roskoski</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update</article-title><source>Pharmacological Research</source><volume>152</volume><elocation-id>104609</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104609</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schehlein</surname> <given-names>EM</given-names></name><name><surname>Robin</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Rho-Associated kinase inhibitors: evolving strategies in Glaucoma treatment</article-title><source>Drugs</source><volume>79</volume><fpage>1031</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1007/s40265-019-01130-z</pub-id><pub-id pub-id-type="pmid">31134520</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidl</surname> <given-names>D</given-names></name><name><surname>Schmetterer</surname> <given-names>L</given-names></name><name><surname>Garhöfer</surname> <given-names>G</given-names></name><name><surname>Popa-Cherecheanu</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pharmacotherapy of glaucoma</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>31</volume><fpage>63</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1089/jop.2014.0067</pub-id><pub-id pub-id-type="pmid">25587905</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segain</surname> <given-names>JP</given-names></name><name><surname>Raingeard de la Blétière</surname> <given-names>D</given-names></name><name><surname>Sauzeau</surname> <given-names>V</given-names></name><name><surname>Bourreille</surname> <given-names>A</given-names></name><name><surname>Hilaret</surname> <given-names>G</given-names></name><name><surname>Cario-Toumaniantz</surname> <given-names>C</given-names></name><name><surname>Pacaud</surname> <given-names>P</given-names></name><name><surname>Galmiche</surname> <given-names>JP</given-names></name><name><surname>Loirand</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in crohn's disease and experimental colitis</article-title><source>Gastroenterology</source><volume>124</volume><fpage>1180</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(03)00283-X</pub-id><pub-id pub-id-type="pmid">12730857</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serle</surname> <given-names>JB</given-names></name><name><surname>Katz</surname> <given-names>LJ</given-names></name><name><surname>McLaurin</surname> <given-names>E</given-names></name><name><surname>Heah</surname> <given-names>T</given-names></name><name><surname>Ramirez-Davis</surname> <given-names>N</given-names></name><name><surname>Usner</surname> <given-names>DW</given-names></name><name><surname>Novack</surname> <given-names>GD</given-names></name><name><surname>Kopczynski</surname> <given-names>CC</given-names></name><collab>ROCKET-1 and ROCKET-2 Study Groups</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)</article-title><source>American Journal of Ophthalmology</source><volume>186</volume><fpage>116</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2017.11.019</pub-id><pub-id pub-id-type="pmid">29199013</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherwood</surname> <given-names>JM</given-names></name><name><surname>Reina-Torres</surname> <given-names>E</given-names></name><name><surname>Bertrand</surname> <given-names>JA</given-names></name><name><surname>Rowe</surname> <given-names>B</given-names></name><name><surname>Overby</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Measurement of outflow facility using iPerfusion</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0150694</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0150694</pub-id><pub-id pub-id-type="pmid">26949939</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamer</surname> <given-names>WD</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Current understanding of conventional outflow dysfunction in Glaucoma</article-title><source>Current Opinion in Ophthalmology</source><volume>23</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1097/ICU.0b013e32834ff23e</pub-id><pub-id pub-id-type="pmid">22262082</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streilein</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Ocular immune privilege: therapeutic opportunities from an experiment of nature</article-title><source>Nature Reviews Immunology</source><volume>3</volume><fpage>879</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1038/nri1224</pub-id><pub-id pub-id-type="pmid">14668804</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamm</surname> <given-names>ER</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The trabecular meshwork outflow pathways: structural and functional aspects</article-title><source>Experimental Eye Research</source><volume>88</volume><fpage>648</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2009.02.007</pub-id><pub-id pub-id-type="pmid">19239914</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamm</surname> <given-names>ER</given-names></name><name><surname>Braunger</surname> <given-names>BM</given-names></name><name><surname>Fuchshofer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Intraocular pressure and the mechanisms involved in resistance of the aqueous humor flow in the trabecular meshwork outflow pathways</article-title><source>Progress in Molecular Biology and Translational Science</source><volume>134</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2015.06.007</pub-id><pub-id pub-id-type="pmid">26310162</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamm</surname> <given-names>ER</given-names></name><name><surname>Fuchshofer</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>What increases outflow resistance in primary open-angle Glaucoma?</article-title><source>Survey of Ophthalmology</source><volume>52</volume><fpage>S101</fpage><lpage>S104</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2007.08.002</pub-id><pub-id pub-id-type="pmid">17998032</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanihara</surname> <given-names>H</given-names></name><name><surname>Inoue</surname> <given-names>T</given-names></name><name><surname>Yamamoto</surname> <given-names>T</given-names></name><name><surname>Kuwayama</surname> <given-names>Y</given-names></name><name><surname>Abe</surname> <given-names>H</given-names></name><name><surname>Suganami</surname> <given-names>H</given-names></name><name><surname>Araie</surname> <given-names>M</given-names></name><collab>K-115 Clinical Study Group</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Intra-ocular pressure-lowering effects of a rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle Glaucoma and ocular hypertension: a randomized, open-label, crossover study</article-title><source>Acta Ophthalmologica</source><volume>93</volume><fpage>e254</fpage><lpage>e260</lpage><pub-id pub-id-type="doi">10.1111/aos.12599</pub-id><pub-id pub-id-type="pmid">25487877</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname> <given-names>NJ</given-names></name><name><surname>Lindsay</surname> <given-names>SM</given-names></name><name><surname>Lees</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Measuring the microelastic properties of biological material</article-title><source>Biophysical Journal</source><volume>63</volume><fpage>1165</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(92)81692-2</pub-id><pub-id pub-id-type="pmid">1420932</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tektas</surname> <given-names>OY</given-names></name><name><surname>Lütjen-Drecoll</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structural changes of the trabecular meshwork in different kinds of Glaucoma</article-title><source>Experimental Eye Research</source><volume>88</volume><fpage>769</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2008.11.025</pub-id><pub-id pub-id-type="pmid">19114037</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname> <given-names>Z</given-names></name><name><surname>Woodward</surname> <given-names>DF</given-names></name><name><surname>Cornell</surname> <given-names>CL</given-names></name><name><surname>Fliri</surname> <given-names>HG</given-names></name><name><surname>Martos</surname> <given-names>JL</given-names></name><name><surname>Pettit</surname> <given-names>SN</given-names></name><name><surname>Wang</surname> <given-names>JW</given-names></name><name><surname>Kharlamb</surname> <given-names>AB</given-names></name><name><surname>Wheeler</surname> <given-names>LA</given-names></name><name><surname>Garst</surname> <given-names>ME</given-names></name><name><surname>Landsverk</surname> <given-names>KJ</given-names></name><name><surname>Struble</surname> <given-names>CS</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Bimatoprost, prostamide activity, and conventional drainage</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>48</volume><fpage>4107</fpage><lpage>4115</lpage><pub-id pub-id-type="doi">10.1167/iovs.07-0080</pub-id><pub-id pub-id-type="pmid">17724194</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Johnstone</surname> <given-names>MA</given-names></name><name><surname>Xin</surname> <given-names>C</given-names></name><name><surname>Song</surname> <given-names>S</given-names></name><name><surname>Padilla</surname> <given-names>S</given-names></name><name><surname>Vranka</surname> <given-names>JA</given-names></name><name><surname>Acott</surname> <given-names>TS</given-names></name><name><surname>Zhou</surname> <given-names>K</given-names></name><name><surname>Schwaner</surname> <given-names>SA</given-names></name><name><surname>Wang</surname> <given-names>RK</given-names></name><name><surname>Sulchek</surname> <given-names>T</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Estimating human trabecular meshwork stiffness by numerical modeling and advanced OCT imaging</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>58</volume><fpage>4809</fpage><lpage>4817</lpage><pub-id pub-id-type="doi">10.1167/iovs.17-22175</pub-id><pub-id pub-id-type="pmid">28973327</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Read</surname> <given-names>AT</given-names></name><name><surname>Sulchek</surname> <given-names>T</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Trabecular meshwork stiffness in Glaucoma</article-title><source>Experimental Eye Research</source><volume>158</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2016.07.011</pub-id><pub-id pub-id-type="pmid">27448987</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>G</given-names></name><name><surname>Read</surname> <given-names>AT</given-names></name><name><surname>Navarro</surname> <given-names>I</given-names></name><name><surname>Mitra</surname> <given-names>AK</given-names></name><name><surname>Stamer</surname> <given-names>WD</given-names></name><name><surname>Sulchek</surname> <given-names>T</given-names></name><name><surname>Ethier</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The relationship between outflow resistance and trabecular meshwork stiffness in mice</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>5848</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-24165-w</pub-id><pub-id pub-id-type="pmid">29643342</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>DJ</given-names></name><name><surname>Xu</surname> <given-names>JZ</given-names></name><name><surname>Wu</surname> <given-names>YJ</given-names></name><name><surname>Jean-Charles</surname> <given-names>L</given-names></name><name><surname>Xiao</surname> <given-names>B</given-names></name><name><surname>Gao</surname> <given-names>PJ</given-names></name><name><surname>Zhu</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice</article-title><source>Atherosclerosis</source><volume>207</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.04.025</pub-id><pub-id pub-id-type="pmid">19473657</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname> <given-names>M</given-names></name><name><surname>Nakao</surname> <given-names>S</given-names></name><name><surname>Arima</surname> <given-names>M</given-names></name><name><surname>Wada</surname> <given-names>I</given-names></name><name><surname>Kaizu</surname> <given-names>Y</given-names></name><name><surname>Hao</surname> <given-names>F</given-names></name><name><surname>Yoshida</surname> <given-names>S</given-names></name><name><surname>Sonoda</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rho-Kinase/ROCK as a potential drug target for vitreoretinal diseases</article-title><source>Journal of Ophthalmology</source><volume>2017</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2017/8543592</pub-id><pub-id pub-id-type="pmid">28596919</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname> <given-names>BY</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The extracellular matrix and its modulation in the trabecular meshwork</article-title><source>Survey of Ophthalmology</source><volume>40</volume><fpage>379</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/s0039-6257(96)80066-x</pub-id><pub-id pub-id-type="pmid">8779084</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Yue</surname> <given-names>BY</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Glucocorticoid effects on extracellular matrix proteins and integrins in bovine trabecular meshwork cells in relation to Glaucoma</article-title><source>International Journal of Molecular Medicine</source><volume>1</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.3892/ijmm.1.2.339</pub-id><pub-id pub-id-type="pmid">9852235</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60831.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Smith</surname><given-names>Lois</given-names></name><role>Reviewing Editor</role><aff><institution>Boston Children's Hospital/Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>McDowell</surname><given-names>Colleen</given-names> </name><role>Reviewer</role><aff><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Tamm</surname><given-names>Ernst</given-names> </name><role>Reviewer</role><aff><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Steroid induced increased intraocular pressure is a significant problem in many eye diseases. Li et al. report that in a small retrospective study netarsudil, a rho-kinase inhibitor, rapidly reversed glucocorticoid-induced ocular hypertension in patients whose intraocular pressures were not controlled by standard medications. The authors show in mechanistic studies in a mouse model of glucocorticoid-induced ocular hypertension that netarsudil both prevented and reversed intraocular pressure elevation. A prospective clinical trial evaluating rho kinase inhibitors versus standard intraocular pressure-lowering agents in steroid-induced ocular hypertension is warranted.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Colleen McDowell (Reviewer #1); Ernst Tamm (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>This paper showed the Rho-kinase inhibitor netarsudil reverses glucocorticoid-induced ocular hypertension in patients, and also investigated the potential mechanism behind this using steroid-induced ocular hypertension mouse model. The authors showed that netarsudil increased outflow facility, decreased mechanical stiffness of the TM, as well as reduced expression of α smooth muscle actin and fibronectin with IHC. The implications of the work have great clinical significance.</p><p>Essential revisions:</p><p>This is an important study that addresses a fundamental problem in glaucoma. In this manuscript the authors provide convincing evidence that a Rho-kinase inhibitor substantially lowers IOP in patients with steroid-induced glaucoma that was uncontrolled by other medications. In addition, they show that this is also the case in a mouse model of steroid-induced glaucoma, with some prior publications in the field. However, there are some major issues that should be addressed</p><p>Since this is about a commercially available drug and partially funded by the company that markets it, the results need to be watertight which they are currently not. It is important that claims not be exaggerated.</p><p>The claim that netarsudil &quot;reverses&quot; glaucoma is not justified in the absence of visual field testing and other functional assessments of the presence, and then absence, of glaucoma. The authors don't show that the mice or the humans are cured and all signs of their disease erased, which is what &quot;reversal&quot; would necessitate. The same principle applies to the word &quot;rescue.&quot; The term &quot;remarkable&quot; should also be removed.</p><p>To claim the antifibrotic potential of netarsudil, the authors need more quantified data to support the &quot;antifibrotic&quot; conclusions.</p><p>Since mouse and human steroid-induced glaucoma is a form of glaucoma with a substantial increase in a specific form of extracellular matrix (basal lamina-like deposits), it is tempting to speculate that those deposits cause stiffness, low outflow facility and high IOP. It would be a major breakthrough, if it could be shown convincingly that the removal of those deposits by rho kinase inhibitors restores TM function. Critical for this point (the &quot;antifibrotic activity&quot;) though is to provide convincing and quantified data. Clearly, structural analysis is the gold standard to show fibrosis or the lack thereof.</p><p>The authors do this by a combination of immunohistochemistry and transmission electron microscopy. It appears though that those studies do not account for the considerable intra-individual differences that the trabecular meshwork outflow pathways show in an individual mouse eye. There are regions of high flow and low flow, and there is a substantial amount of published data showing that these differences are based on structural variations in the outflow pathways. Even in a normal mouse eye, there are regions with less or more fibronectin, α SM-actin etc. The authors are strongly recommended to perform additional molecular analyses. Western blotting or RT-PCR using protein/RNA obtained from corneoscleral rings is what scientists usually do to support data obtained by immunohistochemistry, and to address the problem of regional differences. Since the main ultrastructural finding in steroid-induced glaucoma, also in the mouse eye, are &quot;basal lamina deposits&quot;. Immunostaining for basal lamina molecules such as laminin, nidogen, type IV collagen needs to be done support the TEM data.</p><p>For transmission electron microscopy, one quadrant was processed. It appears that several ultrathin sections were cut from this quadrant. Taking into account the thickness of ultrathin sections (40 – 80 nm) even the analysis of multiple consecutive sections would only have visualized a very tiny portion of TM circumference. Those regional differences need to be taken into account. Clearly there are also quite substantial regional differences when it comes to basal lamina deposits and other forms of fibrillar extracellular matrix in the TM. This is not only true for the circumference, but also for the TM in anterior-posterior direction. For the human patient, the authors quote the work by Johnson, Gottanka et al. which is still important after more than 20 years because of its thorough quantitative analysis. The bars should not be lower in the mouse eye, especially when it comes to the possible identification of a major mechanism. Other less time intensive methods may be available to quantify deposits in all regions, as long as the results represent the variability seen in the mouse eye so the conclusions are reliable.</p><p>If using TEM, the authors need to perform a power analysis in the normal mouse TM that shows how many sectors etc., need to be investigated to quantify basal lamina deposits, open spaces and ruffling of inner wall cells taking into account regional differences and regions with high and low flow. Based on those results quantification needs to be done. This is time consuming, but definitely feasible and the only way to support the statement of &quot;antifibrotic activity&quot;. A semiquantitative analysis without knowing for certain the variability in the system is not recommended.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60831.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>This is an important study that addresses a fundamental problem in glaucoma. In this manuscript the authors provide convincing evidence that a Rho-kinase inhibitor substantially lowers IOP in patients with steroid-induced glaucoma that was uncontrolled by other medications. In addition, they show that this is also the case in a mouse model of steroid-induced glaucoma, with some prior publications in the field. However, there are some major issues that should be addressed</p><p>Since this is about a commercially available drug and partially funded by the company that markets it, the results need to be watertight which they are currently not. It is important that claims not be exaggerated.</p></disp-quote><p>We agree with this assessment and have conducted further experiments (as directed below), and have adjusted language regarding claims (as directed below).</p><disp-quote content-type="editor-comment"><p>The claim that netarsudil &quot;reverses&quot; glaucoma is not justified in the absence of visual field testing and other functional assessments of the presence, and then absence, of glaucoma. The authors don't show that the mice or the humans are cured and all signs of their disease erased, which is what &quot;reversal&quot; would necessitate. The same principle applies to the word &quot;rescue.&quot; The term &quot;remarkable&quot; should also be removed.</p></disp-quote><p>We agree that we have not shown that netarsudil reverses or rescues glaucoma. In most places, we were careful in our writing to say netarsudil reversed or rescued steroid-induced ocular hypertension, or features of steroid-induced ocular hypertension. However, there are several instances where we referred to our steroid-induced “glaucoma” model instead of the more correct “ocular hypertension” model.</p><p>We agree that reversal implies total recovery, which our ultrastructural data clearly shows is not the case. However, NT treatment did bring all of the other endpoint measurements to, or very near to, control levels. Regardless, in response to the reviewer’s concern we have softened our language, both in terms of reversal and other exaggerated claims where appropriate.</p><p>As recommended, we have replaced “remarkable” with “noteworthy”.</p><disp-quote content-type="editor-comment"><p>To claim the antifibrotic potential of netarsudil, the authors need more quantified data to support the &quot;antifibrotic&quot; conclusions.</p><p>Since mouse and human steroid-induced glaucoma is a form of glaucoma with a substantial increase in a specific form of extracellular matrix (basal lamina-like deposits), it is tempting to speculate that those deposits cause stiffness, low outflow facility and high IOP. It would be a major breakthrough, if it could be shown convincingly that the removal of those deposits by rho kinase inhibitors restores TM function. Critical for this point (the &quot;antifibrotic activity&quot;) though is to provide convincing and quantified data. Clearly, structural analysis is the gold standard to show fibrosis or the lack thereof.</p><p>The authors do this by a combination of immunohistochemistry and transmission electron microscopy. It appears though that those studies do not account for the considerable intra-individual differences that the trabecular meshwork outflow pathways show in an individual mouse eye. There are regions of high flow and low flow, and there is a substantial amount of published data showing that these differences are based on structural variations in the outflow pathways. Even in a normal mouse eye, there are regions with less or more fibronectin, α SM-actin etc. The authors are strongly recommended to perform additional molecular analyses. Western blotting or RT-PCR using protein/RNA obtained from corneoscleral rings is what scientists usually do to support data obtained by immunohistochemistry, and to address the problem of regional differences. Since the main ultrastructural finding in steroid-induced glaucoma, also in the mouse eye, are &quot;basal lamina deposits&quot;. Immunostaining for basal lamina molecules such as laminin, nidogen, type IV collagen needs to be done support the TEM data.</p><p>For transmission electron microscopy, one quadrant was processed. It appears that several ultrathin sections were cut from this quadrant. Taking into account the thickness of ultrathin sections (40 – 80 nm) even the analysis of multiple consecutive sections would only have visualized a very tiny portion of TM circumference. Those regional differences need to be taken into account. Clearly there are also quite substantial regional differences when it comes to basal lamina deposits and other forms of fibrillar extracellular matrix in the TM. This is not only true for the circumference, but also for the TM in anterior-posterior direction. For the human patient, the authors quote the work by Johnson, Gottanka et al. which is still important after more than 20 years because of its thorough quantitative analysis. The bars should not be lower in the mouse eye, especially when it comes to the possible identification of a major mechanism. Other less time intensive methods may be available to quantify deposits in all regions, as long as the results represent the variability seen in the mouse eye so the conclusions are reliable.</p><p>If using TEM, the authors need to perform a power analysis in the normal mouse TM that shows how many sectors etc., need to be investigated to quantify basal lamina deposits, open spaces and ruffling of inner wall cells taking into account regional differences and regions with high and low flow. Based on those results quantification needs to be done. This is time consuming, but definitely feasible and the only way to support the statement of &quot;antifibrotic activity&quot;. A semiquantitative analysis without knowing for certain the variability in the system is not recommended.</p></disp-quote><p>The reviewers make multiple excellent points.</p><p>Regarding cohort size/power analysis: We originally chose cohort sizes based upon our previous study (PMID: 25028360), where Prof. Lütjen-Drecoll performed the quantitative analysis of ECM coverage under the inner wall of SC. In that study, significant differences due to dexamethasone treatment were observed using cohorts of 5 control and 7 treated animals (1-3 sections analyzed/eye). In the present study, our cohort sizes (11 placebo and 9 netarsudil-treated mice, 1-3 sections analyzed/eye) were larger than our previous study, and thus we suggest that our sampling is sufficiently representative.</p><p>Regarding segmental variability: the reviewers of course are correct that there is significant segmental variability in the mouse outflow tract. Ideally, one would perfuse flow tracer to label high- and low-flow regions, and quantify ECM in each region. Due to experimental constraints, we were unable to do such experiments as part of this study, although this work is planned. Instead, we have taken the approach of sampling more eyes and more widely spaced sections per eye (see details below) in a masked manner. By so doing, we account for regional variation through appropriate statistical analysis.</p><p>Regarding immunostaining for basal lamina molecules: We agree with the reviewers that these data would complement the TEM study. However, there are several practical considerations that mitigate against this. First, in our experience, the available antibodies to extracellular matrix proteins often take extensive testing and optimization from multiple sources. Second, we are uncertain which components are being altered by DEX, and thus would have to screen different candidates. Since the paper already has 7 supplemental figures, 2 tables and 6 figures (most of which have multiple subpanels), we instead focused our time on improving the TEM analysis, as suggested by the reviewers. Importantly, TEM quantitation in the Overby et al. study (Overby et al., 2014) observed similar changes in BMM from <italic>both</italic> mouse and human eyes exposed to corticosteroids.</p><p>Regarding quantitative scoring of fibrosis: While our semi-quantitative assessment of morphological changes in the conventional outflow pathway at the EM level was scored by two experts in this area, we agree that the paper would be enhanced by quantitative data. In direct response to the reviewer’s request, we have therefore conducted a quantitative analysis of our immunolabelling images and of our TEM images. In the TEM data set, images came from two opposite quadrants of each eye; in several cases, eyes were underrepresented (due to poor quality sections that could not be scored previously), so we cut additional sections from those eyes, as well as cutting sections from additional eyes in the reversal cohort that were not analyzed in the initial semi-quantitative scoring scheme. Using this enlarged image set (97 images from 50 eyes), we went on to quantify basement membrane material following the Lütjen-Drecoll approach (PMID: 25028360). This new quantitative data has been added to Figure 5. As the reviewers can see, the quantification of basement membrane material beneath inner wall produced results that are very similar to our previous semi-quantitative analysis of JCT, and which are quantitatively consistent with the previous report of Overby and colleagues (PMID: 25028360). Importantly, this quantitative data, which was gathered in a fully masked manner, shows statistically significant differences that confirm that treatment with netarsudil partially restored normalcy to the ultrastructure of the subendothelial region. We have added text to the Results as follows:</p><p>“When examined at the electron microscopic level, we observed two major effects of NT treatment on steroid-induced OHT eyes (Figure 5). The first was a significant reduction in the amount and density of basement membrane materials (BMM) underlying the inner wall of SC. The second was an apparent increase in the number of “open spaces” in the TM of NT-treated eyes, particularly in the JCT region. These two changes were scored on a semi-quantitative scale, confirming observational impressions of NT treatment (Figure 5F, p=0.02). In addition, we quantified the amount of BMM below the inner wall of SC in each treatment group following the Lütjen-Drecoll approach (Figure 5—figure supplement 1) (Overby et al., 2014). Similar to results reported in Overby et al., we found that length of BMM underlying SC was significantly increased in mice after DEX treatment (Figure 5G, p&lt;0.001). Indeed, our BMM ratio measurements in control and DEX-treated mice were quantitatively similar to those reported by Overby and colleagues. Most important, these data confirm significant differences between PL- and NT-treated eyes (Figure 5G, p=0.001), whereby NT appears to partially restore the ultrastructure of the subendothelial region (Figure 5).”</p><p>An example methodological image has been provided in the supplemental materials (Figure 5—figure supplement 1), and the methodology for quantitation was added to Materials and methods, as follows:</p><p>“Quantification of extracellular matrix content in JCT</p><p>To quantify ECM in the JCT under the inner wall of SC, images were captured at 8000× magnification and masked as to the identity of the treatment group. Images were quantified in two ways. […] Only continuous BMM in contact with the inner wall was included in the BMM measurements, i.e. regions where continuous BMM showed an optically clear offset from the inner wall were excluded. Ratio values from multiple images from the same eyes were averaged.”</p></body></sub-article></article>